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Community-Based Participatory Research to Partner with the Confederated Salish and 
Kootenai Tribes in Pharmacogenetics Research 
 
Chairperson: Dr. Erica L. Woodahl 
 
 Pharmacogenetics research has advanced our knowledge of the genetic basis of 
individual drug responses. The aim of pharmacogenetics research is to provide 
opportunities for the development of strategies aimed at discovering clinically relevant 
gene-drug pairs. Further benefits stem from the translation of pharmacogenetics research 
into the clinic to identify patients who are at high risk of adverse drug events. However, 
American Indian and Alaska Native (AI/AN) populations have not benefited markedly 
from genetics-guided therapeutics. A key strategy in engaging AI/AN people in 
pharmacogenetics research has been the implementation of community-based 
participatory research (CBPR). CBPR is a qualitative research methodology in which a 
partnership is formed between the research institution and the community under study. 
CBPR provides a framework for both partners to be involved in all aspects of the 
research process, from developing research questions to data analysis, and dissemination 
of research findings. 
 Early in the project, approval was given by the Confederated Salish and Kootenai Tribes 
(CSKT) through discussions with Tribal Health and Tribal Council to conduct 
pharmacogenetics research with the CSKT community. Thereafter, a collaborative 
university-community partnership was established with the CSKT to ensure the 
community has sufficient knowledge about pharmacogenetics research and to develop 
culturally-relevant research strategies. We formed an oversight committee, the 
Community Pharmacogenetics Advisory Council (CPAC), to ensure community 
involvement. We also held workshops to provide education and bring awareness to the 
community about pharmacogenetics research. CPAC engagement and education through 
workshops and research involvement was evaluated through a questionnaire. Seventeen 
healthcare provider interviews have been conducted, transcribed, and analyzed. The 
interviews were conducted with Montana healthcare providers to assess their views on 
the potential benefits and harms of pharmacogenetics research and the feasibility of its 
future implementation into Tribal Health. In addition, two focus groups have been 
conducted thus far. CPAC helped design a moderator’s guide and developed recruitment 
tools for focus groups. These focus group materials were used and will continue to be 
used to conduct focus groups with enrolled CSKT members who receive their healthcare 
through Tribal Health to assess their views and perceptions of pharmacogenetics 
research, its translation into the clinic, and dissemination of results to the broader 
community. The details of the results of the focus groups and healthcare provider 
interviews will be described in this study. 
 This collaboration created a CBPR framework that best fits the needs of the community. 
Engaging CSKT community partners in informal and formal discussions about 
pharmacogenetics research has aided in identifying priorities of the community and 
building mutually productive partnerships  
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CHAPTER 1 
 
INTRODUCTION 
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Personalized medicine offers the opportunity to improve drug responses and 
patient outcomes by tailoring the way healthcare is provided to an individual. The most 
common approach in administering drugs is to start with a standardized dosing regimen. 
Unfortunately people have variable drug responses, some exhibit undesirable or toxic 
effects, and others may not experience any therapeutic effects at all when given a 
standard dose of drug. Many factors contribute to interindividual variation including age, 
sex, diet, environmental factors, drug interactions, liver and renal function, and 
concomitant diseases. It is recognized that interindividual differences are also influenced 
by genetic variation which leads to individual differences in drug disposition (i.e., drug 
absorption, distribution, metabolism, and elimination, or ADME), efficacy, and toxicity. 
Depending on the drug, genetics can contribute to anywhere from 15% to 95% of 
variation in patient drug response (Eichelbaum et al., 2006).  
Genetic variation has been understood for several decades, and the concept that 
testing for genetic variation might be used to guide drug therapy dates back to the late 
1950s where patients who inherited an enzyme deficiency were unable to metabolize 
anti-malarial primaquine and therefore experienced severe hemolysis (Eichelbaum, 2006 
and Beutler, 1969). Later in the 1980s, researchers identified a drug metabolizing enzyme 
cytochrome P450 (CYP450) gene (CYP2D6) polymorphism and its role in the 
metabolism of numerous drugs targeting the central nervous system and cardiovascular 
system (Evans and Relling 1999). These discoveries have markedly contributed to 
increased interests in genome mapping and sequencing; as a result an array of genotypes 
have been identified in key drug metabolizing enzymes and shown to play a role in 
variation of clinical patient outcomes. To this end, huge efforts in genetics research have 
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targeted CYP450 drug metabolizing enzymes due to their polymorphic nature and their 
roles in phase I drug metabolism. Phase I drug metabolism results in more polar 
metabolites of drugs through oxidation, reduction, and hydrolysis which allows them to 
be more readily excreted. In addition, phase I drug metabolism can also lead to either 
activation or inactivation of pharmaceuticals and therefore influence their bioavailability 
(Evans and Relling 1999; Eichelbaum et al., 2006). This highlights the clinical 
significance of genetic variations in CYP450 enzymes that contribute largely to drug 
metabolism. In addition, genetic variation in drug transporters and drug targets has also 
been observed and shown to have clinical significance (Gardiner and Begg 2006). 
Investigating genetic variation in CYP450 enzymes, drug transporters, and drug targets 
offer opportunities to identify potentially important therapeutic effects on drug response. 
 In the following section, I will provide background information regarding 
pharmacogenetics research and its role in personalized medicine thus far. Next, I will 
address the reasons why pharmacogenetics research with American Indian and Alaska 
Native (AI/AN) populations has been limited. Furthermore, I will describe current 
healthcare provider and community views towards pharmacogenetics and its translation 
into the clinic. Finally, I will introduce community-based participatory research (CBPR) 
as an effective model in conducting successful pharmacogenetics research with AI/AN 
populations. This introductory chapter will conclude with discussion of future work in 
this area of research and the specific aims of my thesis. 
 
1.1 PHARMACOGENETICS 
 Major discoveries of genetic factors that  have proven to influence drug response 
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have provided compelling evidence of the potential to personalize medicine and has 
developed into a discipline, termed pharmacogenetics (Evans and Relling 1999). 
Pharmacogenetics involves genetics-related variations in drug metabolizing enzymes, 
drug transporters, and drug targets and how specific genotypes elicit a drug-related 
phenotypic response such as efficacy or toxicity (Crews et al., 2012). Individuals whose 
genotype is known can then be further classified into a phenotype. This phenotype is 
based on an individual’s ability to metabolize a drug and is categorized as follows: poor 
metabolizer (PM), intermediate metabolizer (IM), extensive metabolizer (EM), and ultra-
rapid metabolizer (UM). There can be a number of genetic changes that can be associated 
with the same phenotype. In addition, the frequency of these genetic changes can be quite 
different among ethnic groups. The Food and Drug Administration (FDA) has 
incorporated pharmacogenetics that involves population studies with Europeans, African 
Americans, and Asian-American evaluating medications that cover 19 therapeutic areas 
with an emphasis in the areas of psychiatry, oncology, and cardiovascular diseases. The 
FDA has provided genetic labeling for over 113 drugs that include information about 
drug exposure and response variability, risk for adverse drug interactions, genotype-
specific dosing, and mechanisms of action of drugs (Food and Drug Administration 
2013). For example, the FDA has added to the labeling of codeine to recommend testing 
for patients to identify those with CYP2D6 gene that encodes for a UM phenotype (Crews 
et al., 2012). CYP2D6 is the primary enzyme that converts codeine into morphine (its 
active metabolite). This has sever implications in nursing mothers who take codeine and 
exhibit an UM phenotype resulting in increased morphine levels in their breast milk and 
increasing the risk of morphine overdose in their nursing infant (Koren et al., 2006). This 
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example highlights the potential benefits of pharmacogenetic testing in identifying 
patients who have a genotype that makes them more at risk for adverse drug reactions. 
Furthermore, this labeling information is made available for healthcare providers and 
patients. A partial list of clinically relevant pharmacogenetic examples is shown in Table 
1.1. Some examples are genetic variation in drug metabolizing enzymes (CYP450s and 
thiopurine methyltransferase, TPMT), a drug transporter (organic anionic transporting 
protein, OATP1B1), and drug targets either for efficacy (vitamin K epoxide reductase, 
VKORC1,) or toxicity (HLA variants). However, further education and ease of 
accessibility to pharmacogenetics is still needed if there is to be successful 
implementation of this research into clinics. Fortunately, there are several resources 
available that are working to help facilitate the use of pharmacogenetic testing in clinical 
practice. The following section will discuss two of these resources and give examples of 
two drugs where pharmacogenetic testing has the ability to optimize treatment.  
 
1.1.1. KNOWLEDGE-BASED SYSTEMS FOR PHARMACOGENETIC TESTING 
The goals of pharmacogenetic testing involve reliable interpretation of test results, 
availability of clinical guidelines for personalized dose regimens, and knowledge-based 
decision support systems (Crews et al., 2012). The International Tamoxifen 
Pharmacogenetic Consortium (ITPC) collects information from worldwide studies on 
genetic variants that are associated with tamoxifen metabolism and their effects on 
clinical outcomes of tamoxifen therapy. Tamoxifen is the standard of care treatment for 
estrogen receptor (ER)-positive breast cancer to help prevent recurrence of cancer. 
Tamoxifen (selective estrogen receptor modifier) therapy is important because breast 
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cancer is the most common disease affecting women in the U.S. with an estimated 
232,340 new cases for the year 2013 (National Cancer Institute 2013). The therapeutic 
effects of tamoxifen are elicited through sequential bioactivation by phase I metabolism. 
Tamoxifen’s metabolite, 4-hydroxytamoxifen had initially been identified as the main 
source of therapeutic efficacy due to its 100-fold higher affinity for estrogen receptors. 
However, evidence suggests that a secondary metabolite of tamoxifen, endoxifen, has 
receptor affinity similar to 4-hydroxytamoxifen and is the key source of therapeutic 
effects because its plasma concentrations are 10 times that of 4-hydroxytamoxifen. 
Furthermore, CYP2D6 is responsible for metabolism of tamoxifen into these active 
metabolites (Borges et al., 2006). Therefore, genetic variants of CYP2D6 that cause loss 
of function can result in increased risks of breast cancer recurrence due to lack of efficacy 
(Mürdter et al., 2011). These data encouraged the FDA to add labeling information that 
incorporated genetic factors and drug interactions between CYP2D6 and tamoxifen 
treatment. Understanding the pharmacogenetics associated with tamoxifen can help 
clinicians choose a different therapy for ER-positive breast cancer patients (Goetz et al., 
2008). 
The Clinical Pharmacogenetics Implementation Consortium (CPIC), produces 
peer-reviewed guidelines for providers on the use of pharmacogenetic tests (Relling and 
Klein 2011). For example, CPIC has published guidelines for warfarin, also known as 
Coumadin, an anticoagulant agent used to treat and prevent thromboembolic disorders 
(Johnson et al., 2011). Over 2 million patients will be prescribed warfarin each year in the 
U.S. and of these patients, 20% will experience a severe bleeding event associated with 
overanticoagulation (Kitzmiller et al., 2011; Wysowski et al., 2007). Although a 
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commonly prescribed drug, there exist challenges in its management because it has a 
narrow therapeutic range and a wide interindividual variability. Risks associated with 
warfarin include bleeding or clotting events where patients who are prescribed too little 
medication will form dangerous blood clots, and those prescribed too much medication 
are at risk of severe bleeds (Rettie et al., 2006). In order to prevent such risks, warfarin is 
managed individually by measuring a patient’s prothrombin time and monitoring their 
international normalized ratio (INR), a way to measure the state of coagulation. Sources 
of patient variability include: age, gender, weight, diet, drug interactions, disease-state, 
and ethnic background. In addition, genetic variation in the CYP2C9 drug metabolizing 
enzyme, the major pathway of warfarin metabolism and clearance, contributes to 
differences in warfarin dose requirements. Further studies have also identified a 
noncoding variant of another gene, the vitamin K epoxide reductase complex 1 
(VKORC1) that lowers the expression of the warfarin target, vitamin K epoxide reductase 
protein, which results in warfarin sensitivity. (Johnson et al., 2011; Limdi et al., 2008; 
Higashi et al., 2002). This example illustrates the point that some cases will call for a 
comprehensive examination of more than one source of genetic liability for the same 
drug to explain a patient’s drug response. In response to these genetic observations, the 
FDA has added prescribing guidelines to the administration of warfarin. These guidelines 
encourage healthcare providers to utilize genetic tests to improve warfarin dosing in 
individual patients. A list of currently available pharmacogenetic tests that have been 
incorporated in product labeling is depicted in Table 1.2.  
The full promise of pharmacogenetic tests will emerge within the mainstream 
medical community by ensuring safety and efficacy of therapies particularly those with a 
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narrow therapeutic window (Fargher et al., 2007). In order for this to occur, inclusion of 
all ethnicities needs to be an added focus of pharmacogenetics research. There already 
exists evidence of interethnic differences in relation to variation in drug response. For 
example, in the case of midazolam and CYP3A5, it has been discovered that Caucasians 
express more of the nonfunctional gene as compared to African American populations 
and therefore dosage regimens will need to factor in population differences and tailor 
prescriptions appropriately (Lin et al., 2002; Kuehl et al., 2001; Lamba et al., 2002). 
Discoveries such as this highlight the value of including all world populations in 
pharmacogenetics research and so far pharmacogenetics studies have made efforts to 
include European, African American, Asian populations, with a few studies of genetic 
variation within indigenous populations in the Americas (Jaja et al., 2008; Fohner et al., 
2013). However, a premise of this work is that beneficial pharmacogenetic testing should 
be accessible to all members of society, and therefore research is needed to address 
knowledge gaps related to the use of pharmacogenetics for American Indian and Alaska 
Native (AI/AN) populations in the United States. AI/AN populations are commonly 
understudied and therefore to ensure their inclusion in pharmacogenetics research, a 
partnership between the University of Montana and the Confederated Salish and 
Kootenai Tribes (CSKT) was established. 
Pharmacogenetics represents a major component of the movement to 
―individualize medicine‖, whereby determining which individuals will be responders, 
non-responders, or toxic responders to medications before treatment is the key to 
preventing adverse drug reactions. According to the FDA, in 2006 adverse drug reactions 
became the fourth leading cause of deaths in the U.S., thereby illustrating the importance 
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of pharmacogenetics in healthcare. However, in order for pharmacogenetics to reach 
beyond research and into the clinic, it is of value to explore people’s views and 
understanding of this concept. 
 
1.1.2. VIEWS OF HEALTHCARE PROVIDERS ON PHARMACOGENETICS 
As the study of pharmacogenetics advances, there is a growing need to inform and 
prepare healthcare providers for the anticipated implementation of pharmacogenetics into 
the clinic. It is important to discuss strategies of how best to provide appropriate 
education, technical knowledge, and awareness to healthcare professionals for successful 
clinical translation and therefore views and perspectives from healthcare professionals is 
of value (Burke et al., 2002). Currently, there are few studies available that focus on 
views or opinions of healthcare professionals on this topic and it is for this reason that the 
clinical translation of pharmacogenetics has been difficult. One assumption is that there is 
a lack of knowledge on the side of clinicians that result in a resistance to change and 
clinical uptake of this technology that might benefit their patients (Hedgecoe, 2007). 
Another factor that plays a role is ethics, and clinicians who are familiar with 
pharmacogenetics and its benefits are still reluctant to adopt pharmacogenetic tests due to 
ethical concerns (i.e. privacy, misuse of specimens, potential harms) (Buchanan et al., 
2002). A study was done to address and understand the root of these ethical concerns 
(Hedgecoe 2007). The focus of the study was discussing the use of apolipoprotein E 
(APOE) 4 allele testing which would determine whether a person would be a poor 
responder to the drug tacrine, used for the treatment of Alzheimer’s disease. This 
pharmacogenetic link was first noted in 1995 and is a result that has been highly cited in 
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the realm of pharmacogenetics. However, APOE4 is also a susceptibility gene for 
Alzheimer’s disease, and this fact has created opposition amongst the clinical community 
to use APOE4 testing due to ethical issues around disclosure of disease risk. One 
clinician explained, ―that’s the problem with the APOE4, it’s not just a pharmacogenetic 
tool, it’s also a risk factor for the disease‖ (Hedgecoe, 2007). Another study done by the 
National Health Service (NHS) National Genetics Education and Development Centre, 
had interviewed approximately 19 pharmacists about their views of pharmacogenetics 
(Newton et al., 2007). The general results were that the pharmacists did believe that 
pharmacogenetic testing could provide benefits in drug efficacy and safety, but there 
would first need to be evidence that explained clinical utility and cost-effectiveness. 
These benefits, however, could be enhanced if people have a better understanding of 
basic genetic concepts and terminology. In addition, training and education in 
pharmacogenetics for healthcare professionals is necessary if pharmacogenetics is to be 
successfully implemented and utilized (Dodson, 2011). Furthermore, an assessment of 
the educational needs of the patients, healthcare professionals, and clinics are necessary 
prior to any pharmacogenetics implementation. 
 
1.1.3. VIEWS OF PATIENTS ON PHARMACOGENETICS 
The majority of the U.S. population received their last formal science education in 
high school and further information regarding science education is pulled from outside 
resources (i.e. media, peers) (Trumbo 2000; Reilly, 2000). Therefore concept of health 
and the health care provided are rooted in outdated educational sources and may inhibit 
people from receiving optimal health outcomes for themselves. In order to understand 
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patients’ reluctance to participate in pharmacogenetics research there should be 
discussions with patients to determine what necessary actions are needed to address their 
reluctance. Currently there is limited literature on patients’ views on pharmacogenetics 
and pharmacogenetics testing; with a focus on how patients understand basic genetic 
concepts and genetic risks, which have suggested that patients are not very familiar with 
the concept of genetics and its links with medications (Fargher et al., 2007; Lanie et al., 
2004; Emery et al., 1998). Therefore, opportunity exists to include a wider range of 
public participation since they are the target population in administering pharmacogenetic 
testing (Almarsdóttir et al., 2005). One U.S. study examined 62 adults (African 
Americans and Caucasians) who were asked questions related to basic genetic concepts 
(Lanie et al., 2004). There were some difficulties in defining the term ―genetics‖, 
however about three quarters of respondents were able to give at least one defining 
characteristic by using a family example. When asked questions about the location of 
genes, 14% said genes were located in DNA or chromosomes, 24% mentioned genes in 
association with the brain and/or mind, and 34% of responses indicated that genes were 
in every cell. These data may illustrate that the public does have some grasp of genetics-
related concepts, but also has shown how there still exists difficulty in differentiating 
these concepts. In the UK study (Fargher et al., 2007), 25 patients were interviewed on 
the topic of pharmacogenetics and pharmacogenetic testing. Three emerging themes were 
acknowledged: 1) familiarity with pharmacogenetics, 2) perceived beliefs of 
pharmacogenetic testing, and 3) characteristics of future pharmacogenetic tests. In theme 
1, most of the patients’ first impression of pharmacogenetics related to their knowledge 
of genetics and how we inherit certain things from our parents, while only half of patients 
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were able to define pharmacogenetics independently. In theme 2, patients noted 
perceived benefits, a few of which are personalized side-effect profile, reducing time to 
efficacious dose, and potential to predict most suitable therapies. Patients were noted as 
being enthusiastic about potential benefits, but also stressed how they expected 
pharmacogenetic tests to be delivered and explained with confidence by their healthcare 
provider. This finding in itself emphasizes the need of pharmacogenetic education for 
healthcare professionals in order for clinical uptake of pharmacogenetic testing services 
to occur. Lastly in theme 3, when patients were asked their opinion of how 
pharmacogenetic testing should be provided, it was clear that trust and familiarity were 
important in relation to healthcare provider and clinic. They had concerns with the 
turnaround time (~1-2 weeks) and how this could cause a potential delay in treatment. If 
the public are unable to understand concepts and terminology related to 
pharmacogenetics and pharmacogenetic testing, how are they to ask their doctors key 
questions or reap the potential benefits of this technology? This question is important to 
ask and address in terms of developing successful strategies that can educate the public. 
One way to do this with the public is by exploring the views and opinions of the patient 
community so they are better equipped to take advantage of all possible medical options 
to improve their outcomes. 
 
1.2. COMMUNITY-BASED PARTICIPATORY RESEARCH 
A majority of U.S. pharmacogenetics research has been conducted in European, 
African-American, Asian-American populations with limited data on AI/AN populations. 
The striking lack of data on genetic variation in U.S. AI/AN populations may be due in 
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large part to a legacy of mistrust toward U.S. institutions. Historically, U.S. institutions’ 
role as definers and interpreters of community issues as well as ―appropriators of human 
remains, cultural knowledge, and cultural artifacts‖ (Boyer et al., 2011) has generated 
mistrust among many AI/AN people. Furthermore, traditional research practices resulted 
in failure to return results in a culturally understandable format or conduct research 
beneficial for the community (Bowekaty and Davis, 2003). In addition, two widely 
discussed examples of improper use of genetic research among indigenous people has 
made these communities appropriately wary of new research projects. In 1990, the 
Havasupai Tribe in Southwestern U.S. was experiencing a high prevalence of diabetes 
and agreed to give their blood samples to Arizona State University (ASU) researchers so 
they could understand this health issue. It was later discovered that the blood samples 
were subsequently used beyond diabetes to study mental illness, inbreeding, and Indian 
migration patterns. These very studies betrayed the trust and challenged the culture of the 
Havasupai Indians. In response, the Havasupai Tribe filed lawsuits against ASU and the 
researchers with the main legal claim being the violation of informed consent 
(Bommersbach, 2008). This case was settled with a monetary award to the Havasupai 
tribe members and also a return of their blood samples (Harmon, 2010). The other 
example involves the Nuu-Chah-Nulth people from British Columbia, Canada who 
agreed to participate in a genetic study in 1980 to address the high rates of rheumatoid 
arthritis in their community (Wiwchar, 2000). They donated over 800 blood samples to 
the University of British Columbia (UBC) to conduct this research study. However, UBC 
researchers were unable to find a genetic basis for arthritis in the tribal community, so 
blood sample were used to conduct studies regarding Indian migration patterns, 
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HIV/AIDS, and drug abuse research. These studies covered sensitive issues and exploited 
the Nuu-Chah-Nulth people. In 2004, a resolution between UBC and Nuu-Chah Nulth 
people was made to return blood samples back to the tribe. Furthermore, the tribe formed 
a Research Ethics Committee to review all future research studies to protect the tribe 
from harmful research (Wiwchar, 2004). These examples highlight the importance of 
transforming the way genetic research has historically been conducted with tribal 
communities. 
Despite this negative history, researchers can still work with AI/AN populations 
and have moved towards the use of research models that recognize tribal sovereignty and 
self-determination (Davis and Reid, 1999). One such model, community-based 
participatory research (CBPR), is a qualitative research methodology in which the 
research institution and the community are fully partnered in every aspect of the research 
process, from determining research questions to analyzing, interpreting, and 
disseminating research findings. To this end, CBPR provides a framework to conduct 
collaborative research that builds upon trust, strength of both collaborators, and equality. 
CBPR has emerged as an ideal approach to identify and understand the priorities of a 
community and to address health inequalities that exist in these communities. Further 
advantages of research partnerships include enhanced practicality, quality, and validity to 
the research; engaging partners who can influence meaningful policy change; and 
building capacity among partners (Hoeft et al., 2013). Traditional models have consisted 
mainly of a paternalistic approach where researchers come in with all the questions and 
answers. The design of CBPR allows for researchers to work directly with communities 
to gain understanding and experience at the level of the community. In doing so, 
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communities are more equipped to engage in the research, gain knowledge, and come 
upon research results that are meaningful and reflect their priorities. From this 
perspective, a CBPR approach highlights the value of community action, cooperation, 
and responsibility amongst partners and therefore provides an appropriate framework in 
which to work with AI/AN communities (Boyer et al., 2007). 
 
1.2.1  COMMUNITY-BASED PARTICIPATORY RESEARCH IN HEALTHCARE  
Interest among academic research institutions in discovering new strategies to 
study and address complex health problems has increased with community demands for 
research that is conducted with communities rather than merely on communities. 
Specifically, research institutions are beginning to adopt research models that include 
expertise at the local level through the process of CBPR (George et al., 1996). The 
evidence of CBPR’s emerging recognition is through support by the Institute of Medicine 
(IOM) in advocating that CBPR should be taught to all incoming healthcare professionals 
(Insitute of Medicine, 2002). The IOM described the utilization of CBPR in public health 
as ―epidemiology enriched by contemporary social and behavioral science because it 
incorporates what we have learned about community processes and engagement, and the 
complex nature of interventions with epidemiology, in order to understand how the 
multiple determinants of health interact to influence health in a particular community‖ 
(Minkler and Wallerstein, 2008). Various new journals have been developed and devoted 
to CBPR (i.e. Progress in Community Health Partnerships, Action Research, and 
CES4Health) in the U.S. Furthermore, many divisions of the National Institutes of Health 
(NIH) have increasingly called for grant proposals requiring the use of a CBPR 
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framework to investigate and address health disparities and inequalities (Minkler and 
Wallerstein, 2008; Wallerstein and Duran, 2006). Success in addressing health 
inequalities in communities occurs when appropriate steps are taken to fully engage 
community partners to explore and take action in addressing the health issues of most 
concern in a community where they are deeply rooted. 
 
1.2.2.  COMMUNITY-BASED PARTICIPATORY RESEARCH WITH AI/AN 
COMMUNITIES  
CBPR has been an effective model in conducting successful and scientifically 
sound research in AI/AN communities in the areas of substance abuse prevention (Mohatt 
et al., 2004; Ellis, 2003; Santiago-Rivera et al., 1998), environmental health (Severtson et 
al., 2002), breast cancer screening (Lantz et al., 2003), diabetes (Satterfield et al., 2003; 
Jernigan, 2010), and nutrition (Jernigan et al., 2012). These studies have published 
findings on health outcomes as well as development of culturally relevant CBPR 
methodology within their partner communities. Therefore, we chose to implement a 
CBPR approach in engaging AI/AN communities in pharmacogenetics research to help 
overcome issues of mistrust from previous research. In order for pharmacogenetic 
research to reach its optimal utility in AI/AN communities, a full understanding of 
genetic variation in these communities is necessary. To address the lack of AI/AN 
participation and inclusion in pharmacogenetics research, we have developed a 
partnership with the Confederated Salish and Kootenai Tribes (CSKT) living on the 
Flathead Indian Reservation in northwestern Montana.  The CSKT community is 
comprised of three different tribes: Salish, Kootenai, and Pend d’Oreille. This academic-
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community partnership is the first of its kind to focus on understanding pharmacogenetic 
variation in AI/AN populations in the U.S. The CSKT Tribal Council recently approved 
submission of a research publication that has emerged from this partnership (Fohner et 
al., 2013). Through the use of CBPR there is a potential to establish trust and reorganize 
power relationships such that community members become equal partners. CBPR 
involves the community at each stage of the research process, and must begin at the 
earliest stages if communities are to build capacity and ensure that the research reflects 
community priorities (Boyer et al., 2011). On-going consultation and qualitative research 
with CSKT partners will provide identification of barriers and interests in 
pharmacogenomics research and the use of pharmacogenetic tests in Tribal Health 
Clinics.  
As the field of pharmacogenomics progresses, the involvement of AI/AN 
communities in pharmacogenomics research has the potential to bring forth culturally-
relevant strategies in implementing pharmacogenetic tests in Tribal Healthcare and local 
facilities. Declining costs of pharmacogenetic tests and evidence for clinical utility will 
provide a strong and compelling case for introduction of pharmacogenetic testing in 
AI/AN communities. By building an infrastructure and a CBPR-based partnership, we 
learn more about therapeutic problems and priorities within our partner communities. 
 
1.3.  SPECIFIC AIMS 
The goal of these studies was to test the hypothesis that CBPR methods provide a 
strong basis for addressing knowledge gaps related to pharmacogenetics in AI/AN 
communities. To accomplish this goal, several CBPR approaches were used and are 
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described in three specific aims. The goals of Aim 1 were to build capacity in the areas of 
pharmacogenetics research in the CSKT and to work with members of the Community 
Pharmacogenetics Advisory Council (CPAC), the oversight committee for the project, to 
develop culturally appropriate materials for use in qualitative research. In Aim 2, we 
conducted healthcare provider interviews with Montana providers who serve CSKT 
peoples to explore the acceptability and feasibility of implementing pharmacogenetic 
testing into Tribal Health. Finally in Aim 3, we conducted focus groups with enrolled 
CSKT members to explore their interest in participating in pharmacogenetics research, 
views of pharmacogenetic testing, and ideas of dissemination. These CBPR 
methodologies included community education in the form of genetics-related and CBPR-
related workshops. The following chapters outline the steps completed thus far to achieve 
the aforementioned aims of the thesis. 
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Table 1.1. List of Clinically Relevant Pharmacogenetics Examples 
Gene Drug 
DPYD-5FU 
 
CYP2C9 
 
 
 
CYP2C19 
 
 
CYP2D6 
 
 
 
 
TPMT 
 
 
 
UGT1A1 
 
 
OATP1B1 
 
HLA-B 
 
 
 
VKORC1 
Capecitabine 
 
Warfarin 
Phenytoin 
Tolbutamide 
 
Clopidogrel 
Diazepam 
 
Codeine 
Tamoxifen 
SSRIs 
Tricyclic antidepressants 
 
Azathioprine 
Mercaptopurine 
Thioguanine 
 
Irinotecan 
Nilotinib 
 
Simvastating 
 
Abacavir 
Allopurinol 
Carbamazepine 
 
Warfarin 
Table adapted and compiled from the Clinical Pharmacogenetics Implementation 
Consortium guidelines and www.pharmgkb.org 
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Table 1.2. Product Labeling: Available Pharmacogenetic Tests 
Genetic Biomarkers Clinical Context 
CYP2C9/VKORC1 
 
 
CYP2D6 
 
 
 
 
HLA-B*1502 
 
 
HLA-B*5701 
 
 
TPMT 
 
CYP2C9 and VKORC1 testing is recommended to optimize 
dosing regimen for warfarin. 
 
CYP2D6 testing is recommended for high-risk populations to 
prevent toxicities in treatment with codeine and to improve 
therapeutic efficacy for breast cancer patients in treatment 
with tamoxifen. 
 
HLA-B testing is recommended before initiating treatment 
with carbamazepine (Tegretol, Equetro) 
 
HLA-B testing is recommended for high-risk populations 
before initiating treatment with abacavir (Ziagen) 
 
TPMT testing is recommended before starting treatment with 
azathioprine (Imuran) 
Table adapted and compiled from U.S. FDA Table of Pharmacogenomic Biomarkers in 
Drug Labels and http://www.pharmkgb.org 
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CHAPTER 2 
 
COMMUNITY-BASED PARTICIPATORY RESEARCH TO FACILITATE 
COMMUNITY INVOLVEMENT AND ENGAGEMENT WITH CONFEDERATED 
SALISH AND KOOTENAI TRIBAL MEMBERS  
 
This chapter is being prepared for publication 
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2.1.  INTRODUCTION 
Over the past decade, substantial advances in genetic research have enhanced 
understanding of genetics as an important contributor to individual variation in 
medication response, leading to the area of research called pharmacogenetics  (Evans and 
Relling, 1999; Lesko and Schmidt, 2012). The translation of pharmacogenetics research 
into genetic tests has the potential to help clinicians identify patients at risk of treatment 
failure due to excessive toxicity or lack of efficacy (Crews et al., 2012; Roth et al., 2011). 
Genetic research typically does not directly answer health questions that are priorities for 
a community. Pharmacogenetic research, however, is one type of genetic research that 
could have clinical applications that are of particular benefit to a community should the 
results lead to ways in which health providers can improve drug response and avoid 
adverse drug reactions. Thus, pharmacogenetic research may fit better within a 
community-based participatory research (CBPR) approach to identify health priorities of 
the community and also lends itself to power-sharing or bidirectional learning and 
teaching. While there is much evidence that pharmacogenetic variation is diverse across 
ethnic groups, American Indian and Alaska Native (AI/AN) people have largely not been 
included in pharmacogenetic studies, thus limiting the possibility for implementation of 
pharmacogenetic testing. To address this lack of AI/AN populations in pharmacogenetics 
research, we have developed an academic-community partnership with the Confederated 
Salish and Kootenai Tribes (CSKT) living on the Flathead Reservation in northwestern 
Montana. 
A premise of this work is that pharmacogenetic testing should be accessible to all 
members of society, but that lack of evidence from AI/AN populations may limit the 
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benefits of pharmacogenetics for these groups. Research involving AI/AN populations is 
needed, but there is a legacy of mistrust among AI/AN communities towards academic 
research, particularly towards genetic research, and a perception that past health research 
has provided little benefit (Tsosie, 2007; Reardon and TallBear, 2012). Furthermore, 
conventional research practices often fail to address community priorities or to return 
results to the community in an understandable, culturally relevant form (Bowekaty and 
Davis, 2003; Boyer et al., 2011). In addition, two high-profile examples of inappropriate 
genetic studies in AI/AN communities have made AI/AN communities wary of genetic 
research. The first example was a rheumatoid arthritis study in the Nuu-Chah-Nulth First 
Nation in British Columbia, Canada, where University of British Columbia researchers 
conducted additional studies on HIV/AIDs, drug-abuse, and human migration without the 
permission of the tribe (Wiwchar, 2000). The second example involved a diabetes study 
in the Havasupai Tribe in Southwestern United States. Arizona State University (ASU) 
researchers partnered with the Havasupai to conduct a genetics study to address questions 
pertaining to diabetes; however, researchers used donated Havasupai blood samples for 
additional studies on inbreeding, schizophrenia, and historical migration (Harmon, 2010). 
In both instances, researchers went beyond their agreements with the communities to 
share samples with other investigators and conduct research outside the scope of 
community approval. Fortunately, in the Havasupai case, the National Congress of 
American Indians passed a resolution to support the Havasupai Indian Tribes in their 
lawsuit against ASU; claiming that ASU researchers misused tribal blood samples 
(National Congress of American Indians, 2006). These examples have resulted in adverse 
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impacts on indigenous communities and highlight the importance of transforming the 
way genetic research is conducted within tribal communities. . 
A key strategy in addressing the mistrust of researchers and transforming research 
practice has been implementation of CBPR to identify and understand the priorities of a 
community and to address health disparities that exist in these communities. CBPR refers 
to collaborative research where communities are treated as equal partners and are 
involved in all stages of the research project to ensure that community needs are 
prioritized (Boyer et al., 2011; Christopher et al., 2011). Furthermore, AI/AN 
communities advocate for a CBPR model when conducting research because it facilitates 
their participation in and overseeing of the research process; thereby reducing the risk of 
abuse and helping to build trust (Burhansstipanov et al., 2005). We established a 
partnership between the University of Montana (UM), the University of Washington 
(UW), the Montana Cancer Institute Foundation (MCIF), and the CSKT Tribal Health 
and Human Services based on CBPR principles in order to conduct pharmacogenetic 
research. This effort is part of a center that has partnered with AI/AN communities in 
Alaska, Montana, and Washington called the Northwest–Alaska Pharmacogenomics 
Research Network (NWA-PGRN) to study pharmacogenetics in rural and underserved 
AI/AN populations. The NWA-PGRN is part of a national network, the 
Pharmacogenomics Research Network (NWA-PGRN), funded by the National Institutes 
of Health to use genetic information to improve response to medications. We have 
recently published one of the first studies in the United States about pharmacogenetic 
variation in an AI/AN population (Fohner et al., 2013). This study was made possible 
through the partnership we have initiated in the CSKT community where the community 
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identified response to cancer medications as one of their health priorities. This 
partnership provides opportunities for the community to learn about research, specifically 
pharmacogenetics, and also provides guidance to the researchers about cultural 
appropriateness and cultural beliefs. . 
 
2.2.  MATERIALS AND METHODS 
 
2.2.1.  ESTABLISHMENT OF RESEARCH PARTNERSHIPS 
The partnership between researchers at UM and MCIF and personnel at CSKT 
Tribal Health and Human Services began with initial meetings in 2007 to discuss how 
pharmacogenetics research might be conducted on the Flathead Reservation to evaluate 
the potential benefits of this type of research. These meetings were between researchers 
from the Department of Biomedical and Pharmaceutical Sciences at UM, an oncologist 
and clinical coordinator at MCIF, and the Department Head and Medical Director from 
Tribal Health. We made presentations to the CSKT Tribal Council to ensure community 
priorities were being met and to gain community approval of the research focus. The 
NWA-PGRN employs a total of 3 tribal members between the UM and CSKT Tribal 
Health research team which has played a fundamental role in appropriately navigating 
through tribal approval systems and further guiding the research project to reflect CSKT 
community needs. 
As the partnership progressed and we started to seek research funding, discussions 
were initiated between the groups in Montana (UM, MCIF, and CSKT Tribal Health), 
researchers at the UW, and other research partners in Washington and Alaska to submit a 
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grant to the NIH PGRN to form the NWA-PGRN center. We sought approval from 
CSKT Tribal Council in May 2009 to apply for the grant and Council provided a letter of 
support for the submission. Funding for the NWA-PGRN started in July 2010. CSKT 
Tribal Health received a subcontract from the NWA-PGRN grant that includes support of 
a portion of the salary of the collaborating physician and blood-drawing supplies. In 
addition to Tribal Council approval, approval was obtained from the Institutional Review 
Boards of UM and UW. 
 
2.2.2.  FORMATION OF COMMUNITY PHARMACOGENETICS ADVISORY   
COUNCIL  
One of the major goals of the NWA-PGRN in Montana was to establish a 
community oversight committee, the Community Pharmacogenetics Advisory Council 
(CPAC), to assure Tribal input into the research project and strengthen the academic-
community partnership. The Department Head and Medical Director of CSKT Tribal 
Health provided suggestions of people whom they thought would be valuable to have on 
the CPAC; they suggested representatives from both the Salish and the Kootenai Cultural 
Committees, staff at Tribal Health and Tribal Council, cancer survivors, and a student at 
Salish Kootenai College would provide a wide perspective from across the community. 
Tribal Health initially sent invitations out to six people to join the CPAC and all of them 
accepted; the first CPAC meeting was held November 2010. Since that first meeting, 
however, three people have had to leave the group because of other time commitments, 
and an additional four people were invited to join. Currently, seven people are members 
of the CPAC.  
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We hold monthly meetings with the CPAC to review study progress and goals on 
an ongoing basis. CPAC meetings provide a forum to discuss Tribal interest in 
pharmacogenetic research, culturally appropriate research practices, and the potential for 
the use of pharmacogenetic testing in Tribal healthcare settings. The CPAC has helped in 
the development of tools for focus groups that will be discussed later. Additionally, 
members of the CPAC accompanied UM researchers and Tribal Health staff when we 
presented to Tribal Council in February 2013 in order to get approval to submit a 
manuscript of the pharmacogenetic variation observed in CSKT people (Fohner et al., 
2013). 
 
2.2.3.  CAPACITY BUILDING AND COMMUNITY ENGAGEMENT 
We have engaged in a number of community engagement and capacity building 
activities geared toward increasing community knowledge and involvement in the 
pharmacogenetics project (See Table 1). One of the major goals was to educate CPAC 
members about pharmacogenetics research so that they can be better equipped to advise 
the researchers and educate other Tribal members. We have held two workshops for 
CPAC members: Genetics Education for Native Americans (GENA) (Native American 
Cancer Initiatives, Pine, CO) and nDigiDreams Digital Storytelling (Santa Fe, NM). 
CPAC members were asked to fill out a survey to learn whether they found the 
workshops valuable and if the workshops were usefulness as an educational tool. 
Furthermore, using Likert-scale questions, the survey assessed the degree of knowledge 
CPAC members felt they had in the area of pharmacogenetics and whether participation 
in the CPAC has improved their knowledge.  
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The GENA workshop provided a science curriculum tailored to an AI/AN 
audience to increase training in the area of genetics. The workshop consisted of 
educational presentations on the basics of cell biology and genetics, pharmacogenetics, 
and CBPR; and interactive exercises to increase learning and understanding. There were 
also designated discussions about ethical issues in research and ways to talk about genetic 
research within the CSKT community. The overall goal of GENA is to assist AI/ANs 
with informed decision-making regarding participation in genetic research projects. 
GENA workshops have been used in AI/AN communities for over a decade and have 
been very successful in educating participants in a culturally tailored manner (Dignan, et 
al., 2005). A 2-day GENA workshop was held for CPAC members, Tribal Health staff, 
CSKT community members, and researchers from MCIF, UM, and UW in May 2011. 
Educational objectives from the GENA workshop are presented in Table 2.  
 
nDigidreams Digital Storytelling Workshop 
Storytelling has been one of the dominant ways of societal communication since 
ancient times. Among AI/ANs, storytelling has been used to share history, heritage, and 
customs in order to keep their legacies alive (Hodge et al., 2002). We held a workshop 
that takes a modern approach to traditional storytelling called digital storytelling. Digital 
storytelling involves telling a personal story using video, music, and voiceover. The 
workshop was conducted by nDigiDreams (Manuelito and Rodriguez, 2013) an 
indigenous-focused consulting company that trains individuals to use media tools for the 
purpose of creating digital stories focused on health and wellness. A 3-day nDigidreams 
workshop was held in February 2012 with CPAC members, CSKT community members, 
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and researchers from MCIF and UM. This digital story training involved writing and 
recording a narrative, producing a storyboard with images and music, and final assembly 
of a video.  
 
2.2.4.  DEVELOPMENT OF FOCUS GROUP MATERIALS  
Little is known about how AI/AN people view participation in pharmacogenetic 
research. To understand the views of CSKT people about pharmacogenetic research and 
the potential for application in healthcare, UM and UW researchers and the CPAC 
worked together to create a moderator’s guide for community focus group discussions. 
CPAC members gave input on successive versions of the moderator’s guide and 
participated in ―mock‖ focus group themselves as part of the planning process only. 
CPAC members also gave suggestions on the organization of the focus group to promote 
conversation. and recruitment of focus groups, with the CPAC members also agreed to 
help in recruitment for focus groups by inviting people they knew in the community, 
distributing flyers, and placing advertisements in the local Char-Koosta News (Azure, 
2013b). To help in recruitement, CPAC members were given informational packets that 
included information about the pharmacogenetics research project, contact information 
for all researchers, and specific information about what participation in a focus group 
would entail. 
 
2.3.  RESULTS 
 
2.3.1.  COMMUNITY PHARMACOGENETICS ADVISORY COUNCIL 
We established the CPAC to increase Tribal input into the pharmacogenetics 
research project. To support the CPAC in giving feedback to the research team and 
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explaining the NWA-PGRN project to community members, we offered educational 
opportunities to help CPAC members become more comfortable with genetic concepts 
and terminology.  To gauge whether these educational programs were useful and 
effective at community pharmacogenetics, we administered a survey at a regular CPAC 
meeting that ask CPAC members to rate their knowledge of pharmacogenetics prior to 
and after joining the CPAC. The Likert scales were designed on a scale of 1 to 5, with 1 
reflecting ―considerable knowledge‖ of pharmacogenetics and 5 reflecting ―no 
knowledge‖ of pharmacogenetics . The average score of CPAC members knowledge 
prior to joining the CPAC was 4.5 (median: 5), suggesting they had little to no 
knowledge of pharmacogenetics research. The average score after joining the CPAC was 
2.75 (median: 3), suggesting that CPAC members felt their knowledge of 
pharmacogenetics had improved. Not only did the average score improve, but every 
individual member of the CPAC reported an increase in knowledge prior to and after 
joining CPAC.  
Furthermore, CPAC members’ views about pharmacogenetics research may have 
shifted. Prior to joining the CPAC, members voiced two major themes in the survey:  
either they had not heard of this type of research or they had heard of it but were 
―Skeptical. Worried that the Indian people might not benefit from the research‖ Another 
member mentioned, ―Actually I never did hear of pharmacogenetics, let alone spell it.‖ 
After joining the CPAC, comments suggest that CPAC members are more supportive of 
pharmacogenetics research. One member who had previously stated feeling ―suspicious‖ 
of pharmacogenetics now reported: ―After seeing the potential for medical breakthroughs 
in helping tribes, I am more inclined to support guided research, especially in the area of 
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informing and educating the population.‖ Another member reported how they now have a 
―More positive outlook with the potential outcomes for the people (reservation and tribal 
people).‖ The feedback the researchers have heard from the CPAC through this survey 
and during meetings is that consistent discussions with the CPAC has been useful in 
educating our partner community in the area of pharmacogenetics research, but that 
continued education in genetics and pharmacogenetics is important.  
 
2.3.2.  GENETIC EDUCATION FOR NATIVE AMERICANS WORKSHOP 
We had two goals for the GENA workshop:  to increase pharmacogenetic 
knowledge within our partner community members and to increase cultural awareness 
and sensitivity within our research team. In previous work, GENA has reported a 35% 
increase in participants’ knowledge, based on pre- and post-workshop surveys 
administered. In the survey that was conducted with the CPAC, we asked questions to 
assess the value of the GENA workshop and all members agreed that it was helpful in 
expanding their knowledge in the area of genetics and pharmacogenetics. For example, 
one member stated, ―I got a good idea about genetics and DNA and Indian people. It has 
spurred me to explore the subject more.‖ This feedback supports the importance of 
providing education to our partner CSKT members. 
 
2.3.3  NDIGIDREAMS DIGITAL STORYTELLING WORKSHOP 
Researchers and CPAC members each produced a 3-5 minute personal narrative 
digital story, and learned the skills to facilitate creation of additional digital stories in the 
community. We have used these digital stories to raise awareness about pharmacogenetic 
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research with the CSKT people and to increase participation in the project during 
recruitment events (e.g. pow-wows, health and career fairs). We also asked CPAC 
members to evaluate this workshop in the survey. Three CPAC members had attended the 
GENA workshop and all felt that the workshop was helpful in developing skills for 
creating digital stories and that it would be a useful method for communicating 
pharmacogenetics research. Therefore, in the future we plan to use these digital stories, as 
well as to generate additional stories, and show them on local access TV stations, 
websites, and in CSKT Tribal Health clinics. 
 
2.3.4  FOCUS GROUP MATERIALS 
Together with the CPAC, we have created a culturally appropriate moderator’s 
guide for focus groups to discuss views of pharmacogenetics. Their involvement ensured 
the moderator’s guide reflected the values and approaches that the CSKT community 
would find understandable and culturally appropriate. The ―mock‖ focus group was 
attended by four of our CPAC members and helped to further elicit feedback for the 
moderator’s guide and focus group organization. For example, CPAC members 
mentioned how in their culture elders are respected by the youth and in a social setting it 
is seen as disrespectful for youth to speak up first in front of an elder. Therefore, CPAC 
members recommended we stratify focus group participants by age (<40 years of age and 
40 years of age) so that the youth and elders are grouped separately, which might 
encourage more dialog from all participants in the focus group. The ―mock‖ focus group 
also prompted CPAC members to provide more informed feedback on the moderator’s 
guide regarding the types of questions asked, the order in which they were asked, and the 
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appropriateness of the language for a generally lay audience with minimal or no genetic 
science background. The questions in the guide revolve around three major themes: 1) the 
field of pharmacogenetics, 2) clinical utility of pharmacogenetic tests 3), dissemination of 
results back to community (See Table 3 for specific examples). We also discussed with 
the CPAC whether to stratify participants in the focus groups, and decided we will 
stratify by age Researchers from the UM, accompanied by some CPAC members, 
presented before CSKT Tribal Council and received approval to start recruitment for 
focus groups in February 2013. The goal of these focus groups is to facilitate tribal input 
regarding cultural barriers and understanding in pharmacogenetics research and its 
translation into the clinic.  
 
2.4  DISCUSSION 
We have established an academic-community partnership between CSKT 
providers and community members and researchers at the UM, UW, and MCIF to 
explore the potential benefits of pharmacogenetic testing in CSKT Tribal Health and 
Human Services, the healthcare entity through which the majority of CSKT members 
receive their healthcare. We have used CBPR approaches, particularly in the formation of 
the CPAC advisory group, to engage academic and community partners to develop 
bidirectional expertise and ensure that the community is an equal partner in the research 
project. We have sought authorization in all aspects of the research project from the 
CSKT Tribal Council, Tribal Health, and members of the CPAC before initiating any 
project activities.  
AI/AN communities have been wary of participation in genetic research because 
of a negative history of researchers and a mistrust of United States academic institutions 
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and the Federal government. CBPR has shown to be a promising research approach by 
providing a framework from which to conduct research within AI/AN communities and 
establishing a mindful path in creating a trusting and equal partnership with the CSKT 
community (Burhansstipanov et al., 2005; Boyer et al., 2011; Thomas et al., 2009). We 
have learned that achieving successful implementation of the CBPR approach requires 
forthright understanding and acknowledgement of AI/AN communities as a sovereign 
cultural people. Only the communities themselves fully understand their cultural structure 
and beliefs, and there is knowledge to be gained for researchers to work productively 
with these communities.    
One of the key features of our CBPR approach was the establishment of the 
CPAC, which has brought invaluable community insight to help guide the research in a 
culturally sensitive direction. Regular meetings between the researchers and CPAC 
increase Tribal input into the research study, give advice about the study approaches to 
ensure cultural appropriateness, and discuss Tribal interest in pharmacogenetic research 
and the use of pharmacogenetic testing in health care. After being involved with the 
CPAC, a member stated that they had a ―more positive outlook with the potential 
outcomes for the people (reservation and tribal people).‖ Since the establishment of the 
CPAC, we have seen an increase in pharmacogenetics knowledge and a shift in negative 
perceptions and attitudes towards this type of research. Educational workshops with the 
CPAC and other community members have helped increase community involvement and 
engagement and provided CPAC members with more tools to make informed discussions 
and recommendations about the research project. The CPAC has also been crucial in the 
development of informational materials that describe the pharmacogenetics research 
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project. Another way in which a CPAC member, Bernie Azure, has also increased 
community awareness and education about the research project through several articles 
he wrote and published in the Char-Koosta News (the CSKT newspaper) (Azure, 2011; 
Azure, 2012a; Azure, 2013c; Azure, 2012b). 
The next step for the research project will be to conduct qualitative research in the 
form of focus groups to assess views about pharmacogenetics research in the CSKT 
community. Recruitment strategies have already been discussed and initiated with the 
CPAC. The CPAC members have collectively handed out educational brochures and 
recruitment flyers throughout the Flathead Indian Reservation (i.e. Tribal Health clinics, 
Salish Kootenai College).The CPAC assisted in creating focus groups materials, 
particularly the moderator’s guide. Their involvement ensured the moderator’s guide 
reflected the values and approaches that the CSKT community would find understandable 
and culturally appropriate.  
An important aspect of this partnership is that the researchers frequently present 
before the CSKT Tribal Council to provide updates about research progress, to gain 
approval for submission of manuscripts, and to ask for approval for new research 
directions. After we published the first academic paper to come out of this partnership 
after receiving Tribal Council and Tribal Health approval (Fohner et al., 2013), we 
worked with the CPAC to deliver the results in formats that would be more 
understandable. CPAC member, Bernie Azure, wrote one article in the Char-Koosta 
newspaper discussing the primary results (Azure, 2013a). We also have discussed using 
our training from the nDigidreams digital storytelling workshop to create new stories that 
could be useful in disseminating research findings in the community.  
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Despite the many benefits to the CBPR approach, associated challenges did arise. 
For instance, current educational efforts have only begun to reach our CPAC and a small 
portion of the CSKT community. In the case of the workshops we conducted, only a 
small number of CSKT community members were able to participate due to limited 
funding resources. However, as we continue to bring awareness and engage more of the 
community, we hope to involve a larger portion of the CSKT community. Another 
challenge involves CSKT community approval, where long approval times are needed in 
order to obtain consent from Tribal Health, Tribal Council, and the Salish and Kootenai 
Cultural Committees for research project activities and publication. Thus, coordination of 
the tribal review process with the university reviews process proved difficult. Although 
this grant has accounted for time in developing a partnership and flexibility for the CSKT 
community to provide input in the research project focus and goals; so as a result 
postponement of deadlines was occasionally necessary.  However, these challenges are 
an important reminder that the partnership with the CSKT community is process oriented 
and therefore success lies in the ability to be patient and work at the pace set by the 
community. 
The goal of this academic-community partnership has been to work 
collaboratively to ensure that the CSKT community has sufficient knowledge about 
pharmacogenetics research and to gain their input to develop culturally appropriate 
strategies for the project. Results generated from the research project have the potential to 
address major unmet medical needs. A key strategy in engaging the CSKT in 
pharmacogenetic research was the implementation of CBPR to identify the priorities of 
the community and to build mutually productive partnerships to address health 
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disparities. AI/AN populations have for the most part been left out of pharmacogenetic 
research, and thus have been overlooked in the advancement of personalized medicine. 
The use of a CBPR approach to involve AI/AN communities in pharmacogenetics 
research has the potential to implement pharmacogenetic tests in Tribal Healthcare and 
local facilities to improve therapeutic efficacy and safety.  
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Table 2.1. Capacity Building and Community Involvement Action Activities 
Components Activities 
Community Education Community Pharmacogenetics Advisory Council 
Materials development and review 
Media (i.e. Char-Koosta News) 
GENA workshop 
Community Training nDigiDreams workshop 
Recruitment materials development and review 
Partnership Advocacy Facilitate connections among researchers, healthcare 
providers, and CSKT community 
 
Establish sustained funding for CBPR continuation  
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Table 2.2. Educational Objectives from the GENA Workshop 
Objectives Descriptions 
Objective 1 What is a cell? Describe parts of a cell
*
 
Objective 2 Review basic principles of cell biology and genetics; e.g., cell structure, 
location of DNA and RNA, protein expression, transcription, and 
translation 
Objective 3 Review basic genetic concepts
*
 
Objective 4 Understand classical patterns of inheritance and cultural traditions 
related to these patterns
*
 
Objective 5 Community-based participatory research case studies 
Objective 6 Describe benefits and drawbacks to pharmacogenetic 
Objective 7 Ethical issues case studies 
Objective 8 Ethics, Opinions 
Objective 9 Questions and discussion about ways to talk about genetics in the CSKT  
* 
Objectives also include an interactive participant exercise 
http://www.natamcancerinitiatives.org/GENA/GENA.html 
 
(Dignan, Burhansstipanov, and Bemis 2005) 
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Table 2.3 Examples of Moderator’s Guide Questions for Focus Groups 
Themes Examples of Questions 
Field of pharmacogenetics  What do you think about genetic research aimed at 
understanding how medications work? 
 What do you think about Salish and Kootenai people 
participating in genetic research? 
 What are some things we should be thinking about 
culturally when doing this kind of pharmacogenetic 
research in Tribal populations? 
Clinical utility of 
pharmacogenetic tests 
 What do you think about a genetic test that would help 
the doctor figure out the right dose of warfarin for a 
person who was at risk of developing a dangerous 
clot? 
 What do you think about a genetic test that would help 
the doctor figure out whether tamoxifen is the best 
medication for a person being treated for breast 
cancer? 
Dissemination of results back 
to the community  
 What kind of information would you want researchers 
to share with your community? 
 What would be the best way for researchers to share 
information with the community and in what format 
would be best? 
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CHAPTER 3 
 
HEALTHCARE PROVIDERS’ VIEWS ON PHARMACOGENETICS RESEARCH 
AND ITS FUTURE IMPLEMENTATION INTO THE CONFEDERATED SALISH 
AND KOOTENAI TRIBAL HEALTH CLINICS 
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3.1.  INTRODUCTION 
Pharmacogenetics encompasses the study of genetic variation and how this relates 
to an individual’s drug response. Pharmacogenetics research has been aimed at 
discovering these sources of genetic variation to guide therapy in patient treatment 
(Vesell, 2000; Cordell and Clayton, 2005). One way that this is being done is through the 
use of pharmacogenetic testing. Pharmacogenetic tests provide the ability to identify 
patients at risk of adverse drug reactions before treatment is initiated. In several 
therapeutic areas (i.e. oncology, cardiology, psychiatry), there are various 
pharmacogenetic tests that have been adopted and applied for patient care (Ventola, 
2011). For example, the antiretroviral drug, abacavir, is primarily used to treat people 
with human immunodeficiency virus and evidence has shown that ~6% of patients 
experience life-threatening hyper-sensitivity reactions; therefore, healthcare providers are 
recommended to test for clinically significant HLA variants in this patient population 
(Martin et al., 2012). This example shows how a test can help avoid an adverse drug 
reaction and the use of such tests are being encouraged by regulatory agencies, such as 
the FDA. 
 However, implementation of pharmacogenetic tests into the mainstream medical 
community has been slow and challenging. Some reasons for this is that there is little 
clinical evidence that evaluate the utility of pharmacogenetic tests, the medical 
community is unaware of pharmacogenetic testing, or there is no clear model of how to 
implement pharmacogenetic testing into the healthcare system (Roth et al., 2011; 
Rogowski et al., 2009; Grossman, 2007). In order to successfully integrate 
pharmacogenetic testing into the healthcare clinics, consultation with the medical 
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community in which you plan to implement is crucial. Healthcare providers facilitate 
medical treatment, understand the socioeconomics of their healthcare sites and patient 
community. Therefore discussions with healthcare providers will provide valuable insight 
to the feasibility of pharmacogenetic testing in their healthcare facilities. 
 There is limited published data about the views of healthcare providers regarding 
pharmacogenetics research and its translation into the clinics. One study that was 
published, explored U.S. healthcare provider views on the risks and benefits of 
pharmacogenetics research using qualitative methods consisting of a three day workshop 
where discussions around this topic were facilitated (Formea et al., 2013). Another U.S. 
study evaluated healthcare provider views on the adoption of pharmacogenetic testing in 
clinical practice by administering of a national survey (~10,000 respondents) (Stanek et 
al., 2012). A U.K. study held interviews and focus groups with healthcare providers to 
explore their views about pharmacogenetics research and its translation into the clinic 
(Fargher et al., 2007). Therefore, it is of value to include a wider range of healthcare 
provider views on the topic of pharmacogenetics and its translation into the broader 
medical community. This study used consultative and qualitative methods to evaluate the 
views of healthcare providers on the potential benefits and harms of pharmacogenetic 
testing, its acceptability in rural and tribal communities, and the feasibility of 
implementing pharmacogenetic testing into clinical practice. 
 
3.2.  METHODS 
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3.2.1.  STUDY SUBJECTS 
 Healthcare providers involved in the study were identified by research 
team members at the University of Montana, CSKT Tribal Health, and the Montana 
Cancer Institute Foundation. Seventeen interviews were conducted: 10 physicians, 3 
registered nurses, 2 nurse practitioners, 1 physician’s assistant, and 1 pharmacist. There 
were a total of 10 females and 7 males with ages ranging from 30-65yrs. Healthcare 
providers represented Missoula clinics (9 total) and Polson clinics (8 total), of these 
providers 7 were associated with Tribal Health. Also, 3 healthcare providers were tribally 
affiliated. All of the healthcare professionals treated AI/AN patients.  
 
3.2.2.  HEALTHCARE PROVIDER INTERVIEWS  
The interviews were conducted to facilitate conversations with healthcare 
providers to try to understand potential benefits and harms of genetic testing and to learn 
about how a patient’s likely drug response might be used in clinical practice. Individual 
healthcare providers were engaged in a series of discussions using structured deliberative 
processes and the interviews consisted of three main sections: 1) attitudes regarding 
pharmacogenetic testing, 2) card sort exercise – assigning values to different kinds of 
pharmacogenetic tests that exemplified drug efficacy (selective serotonin reuptake 
inhibitors, SSRIs), drug dose and monitoring (warfarin), and adverse drug events 
(carbamezapine), and 3) clinical integration. Face-to-face interviews were held at 
healthcare provider’s place of work and lasted approximately one hour. All subjects 
consented to the study using forms approved by the University of Montana  Institutional 
Review Board. 
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3.2.3  Qualitative Analysis 
Trained members of the study team at the University of Washington constructed 
an initial coding template drawing from the interview guide and themes that arose from 
the individual interview sessions. This coding template was reviewed by the collaborative 
research team at University of Montana and University of Washington who had expertise 
in qualitative research to achieve consensus. The interviews have been transcribed 
verbatim and are in the initial stages of coding using thematic analysis. Initial coding was 
performed using the Dedoose© qualitative analytical software package (Los Angeles, 
CA) and the revised coding template. 
 
3.3  RESULTS 
 
3.3.1  HEALTHCARE PROVIDER INTERVIEW ANALYSIS 
The goal of these deliberative processes was to facilitate discussion about the 
potential benefits and harms of pharmacogenetic research and whether its translation into 
CSKT facilities is feasible. Nineteen major themes were captured throughout the analysis 
process that encompassed the views and opinions of all 17 healthcare providers. These 
themes are as follows: 
1. Genetics and genomics-general: Comments related to the ability of healthcare 
providers to differentiate between genomics and pharmacogenomics. Comments 
categorized under this code may also include genetics-related concerns and 
general pharmacogenomics perceptions. Respondents were asked questions about 
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the idea of introducing a whole genome screening test that would be accessible 
for medical purposes. One respondent acknowledged that: 
“...there‟s so many issues there. I mean there‟s medical issues, there‟s ethical 
issues. You know, there are, there could be a lot of psychological issues that arise 
if somebody‟s fearful there whole life they‟re gonna get the same disease that, you 
know, Auntie May got.” (Respondent 670) 
This respondent went on to explain that applying a more targeted approach to 
genetic screening instead of a shotgun approach may elicit a more positive 
response with the medical and patient community. General thoughts on genomics 
and pharmacogenomics by healthcare providers included the push for efforts in 
advancing technology that will incorporate pharmacogenetic testing results.  
 
2. Genomics and pharmacogenomics differentiation: Comments related to the ability 
of healthcare providers to differentiate between genomics and 
pharmacogenomics. Comments categorized under this theme may also include 
genetics-related concerns and general pharmacogenomics perceptions. Most 
healthcare providers were able to differentiate between the concept of genomics 
and pharmacogenomics. Respondents emphasized the point that 
pharmacogenomics is more personal than the basic lab tests (i.e. blood sugar, 
blood type). One respondent explained this personal difference as: 
“I think it has a lot to do with the word genetics in the name [referring to test]. 
Because we do PT/INR, we monitor warfarin or heparin, whatever we got going. 
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Yeah I think that the word genetic...I think cuz it goes to us personally, it‟s like 
finding out our secrets. Maybe we‟re not genetically perfect.” (Respondent 765) 
Other respondents further described pharmacogenetic testing as eliciting more 
information such as having a breast cancer 1 mutation that encodes damaging 
effects of the breast cancer 1 protein, which is important for DNA repair; and 
therefore, increases the likelihood of developing cancer. However, healthcare 
providers still felt that it would be worthwhile to investigate drug response at the 
individual level.  
 
3. Implementation – policy and operations: Comments related to policies, 
procedures, and trainings that would be required in implementing a 
pharmacogenetic test. Healthcare providers’ general response to policies and 
procedures were that pharmacogenetic tests should be equal to other established 
tests in the clinic in their physical use (i.e. ordering process, availability in house). 
Furthermore, most healthcare facilities contain electronic medical records: 
therefore, respondents were more likely to use pharmacogenetic information to 
treat their patients if test results were incorporated into electronic medical records 
in the form of prompts.  It was also emphasized that upon implementation of 
pharmacogenetic testing, a policy and procedure manual should be written 
specifically for pharmacogenetic testing guidelines and be made available in 
clinics. Some respondents mentioned available trainings that occur at their 
healthcare sites that did not include much on the topic of pharmacogenetics. Most 
healthcare providers received information on pharmacogenetics through trusted 
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resources such as the National Comprehensive Cancer Network (a source of 
cancer information and treatment guidelines compiled from multiple leading 
cancer centers), Up-To-Date (an evidence-based resource for clinical information 
compiled by physicians), and peer-reviewed journals. For the latter, one 
respondent mentioned how peer-reviewed journals are important in contributing 
to policy and procedures of pharmacogenetic testings: 
“The most convincing thing is publication in a peer-reviewed journal that is then 
able to be put to the scrutiny of the peers, and after being assessed with that 
scrutiny still seems to be valid. Then those are the things that move into clinical 
care.” (Respondent 582) 
These results show the various avenues of pharmacogenetics education and 
awareness relied on by healthcare providers as well as their opinions in how 
policy and procedures should look for pharmacogenetic testing. A lack of training 
seems to be common across healthcare sites, most likely due to pharmacogenetics 
testing still being in the research stage. 
 
4. Implementation – success factors: Comments related to factors that will be 
important for the implementation of a pharmacogenetic test. Respondents were 
insistent that electronic medical records be utilized in efforts to implement 
pharmacogenetic information and test results in an understandable format. This 
would provide a user-friendly appeal to healthcare professionals and increase their 
support and use of pharmacogenetic tests. Another concern that was mentioned 
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involved researchers’ need to explore bioethical questions within tribal 
communities. One respondent explained: 
“...I think it‟s important to be aware of the historical trauma, mistrust, and also 
being, coming in and talking to the leaders in our community [CSKT community] 
and in a respectful way, not talking above, but talking in layman‟s terms to try to 
best explain what they see as the benefits of bringing this kind of testing to our 
people [CSKT people].” (Respondent 775) 
Furthermore, healthcare providers suggested that evaluating pharmacogenetic 
testing in clinics and proving its usefulness will help to increase its use in 
healthcare institutions. 
 
5. Pharmacogenomics barriers: Comments about factors that could limit the uptake 
of available pharmacogenetic tests. The common barriers that seemed to surface 
across all interviews on the side of healthcare providers and clinics is the issue of 
cost to implement a genetic test and older generations not believing in the benefits 
of pharmacogenomics. 
“Cost is the big thing and geographical location. I mean in Montana, getting 
people...I worked briefly here after I moved back and unfortunately the hospital I 
worked at did not see any benefits to tumor typing and genetic testing before 
doing the chemotherapy...And rather than working as a collaborative for the 
patient‟s benefit, we have some people who are very resistant.” (Respondent 100) 
In terms of patients, ethical issues regarding abuse (i.e. exploitation, 
stigmatization) of their genetic information, mistrust, and reluctance out of want 
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for privacy or other personal reasons were the main barriers that arose from the 
interviews.  
“...Just any genetic sequencing, you know, has potential ethical grey zones, that‟s 
always the argument that seems to come up is, what about abuse? A cheek swab 
doesn‟t just give you  information about drug metabolism, it gives you your entire 
code.”  
(Respondent 865) 
Barriers are important to evaluate and discover in order to successfully implement 
pharmacogenetic testing, our studies have identified various barriers that will 
guide our research in overcoming them. 
 
6. Pharmacogenomic benefits: Comments related to the value of pharmacogenomic 
tests in clinical practice, or how they could offer value in the future. Benefits 
could refer to either specific medications or to more general benefits. Healthcare 
providers talked about the potential benefits in guiding drug therapy, predicting 
adverse side effects (i.e. toxicity), increasing survival rates, and saving time, 
resources, and energy. Healthcare providers further explained how these benefits 
apply to narrow therapeutic range drugs and a focus should be on drugs targeting 
diabetes, cardiovascular disease, and cancer. One provider explains how 
pharmacogenetics can prove useful in the field of oncology: 
“The best data so far is in oncology...looking at pharmacogenetics, is in looking 
at toxicity. And so there is good data that checking for UGT for instance with 
irinotecan can pretty much guess who‟s gonna get the most toxicity for that drug. 
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Also with 5-FU. And then tamoxifen is still a real evolving story, but we do know 
that genetics can determine metabolism. Hasn‟t shown clinically to be meaningful 
yet. So I think there‟s a lot of potential and it‟s a worthwhile – a very worthwhile 
project.” (Respondent 582) 
Providers further explained the value in studying clinically relevant gene-drug 
pairs across the U.S. in increasing popular use of pharmacogenetic testing. 
 
7. Pharmacogenomics education – public and patients: Comments related to 
whether informant feels there is a need for or value in improved patient and public 
education in genetics and pharmacogenomics. A majority of healthcare providers 
expressed the importance of educating the patient community about 
pharmacogenetic test benefits, results, and general information. One respondent 
mentioned how combined efforts in education both patients and providers is 
important for the uptake of pharmacogenetic testing: 
“...Some misconceptions among patient populations, and some of them are well-
founded, because in the past genetic testing may have been used for really 
unethical or inappropriate uses, so there are populations that are very sensitive, 
cautious, and need reassurance that in face these kind of testing mechanisms are 
for their benefit. And so I think one of the things will have to happen is education, 
not only of provider but of patient populations.” (Respondent 700) 
Furthermore, most healthcare providers felt that it was their responsibility to 
translate pharmacogenetics information into a format that is understandable to 
their patients. 
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8. Pharmacogenomics education – providers: Comments related to current 
knowledge, educational priorities, and preferred information sources for providers 
to self-educate. This theme also includes comments related to awareness of 
available pharmacogenomic tests and understanding of pharmacogenomic 
concepts. Healthcare providers expressed how there exists a lack of formal 
education and training in pharmacogenetics and its applications for clinical use. 
They further described that educational needs can be met through continuing 
medical education (CME) courses. For example, CME courses are required for 
physicians, but are not always made available to nurses. One nurse suggested an 
educational approach that could be successful in informing nurses about 
pharmacogenetics: 
“Continuing education, a lot of times nurses, well from a nursing perspective we 
don‟t always get to do those, so like online CEUs (continuing education unit) for 
that would be excellent, where you could go online and read about it, and then do 
questionnaire and get like a CME credit.” (Respondent 692) 
In terms of self-educating, respondents described various educational venues that 
they utilize such as: scientific meetings, CME courses, U.S. organizations (i.e. 
American Academy of Neurology, American Pain Society, American Cancer 
Society), major journal literature (i.e. Journal of American Medical Association), 
and colleagues.  
“...We look to people doing basic science research to find information. We kind of 
expect that a corporation will make the best financial use of that they can, and we 
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look to people doing academic medicine to figure out really who should be getting 
the test [genetic test] and who shouldn‟t.” (Respondent 933) 
 
9. Pharmacogenomic experiences: Comments related to providers experiences using 
pharmacogenomics tests in clinical practice. Some healthcare providers talked 
about their experience with pharmacogenetics: 
“I worked as an oncology nurse for five years out in Oregon under the OHSU 
[Oregon Health and Science University] umbrella. We saw a lot of patients where 
we would do genetic testing for chemotherapy response for their tumors.” 
(Respondent 100) 
 
“I mean 5-FU, Irinotecan are the two drugs that are probably number one for us 
being, for us knowing about it [pharmacogenetic testing]. So whenever I start a 
patient on those I always think about it [pharmacogenetic testing]. The problem is 
getting paid for it, and getting the answer soon enough to be of use.” (Respondent 
376) 
 
10. Pharmacogenomics general – enthusiasm: Comments related to informants’ 
overall level of interest or enthusiasm about pharmacogenomics testing: 
“If I put on my hat as a collaborator in the research world – which I‟m not a 
researcher by any stretch of the imagination, but I‟m interested in the research – 
how our small clinic and our small population here, our community here could 
help make the difference of just learning more information about this, to benefit 
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from it, I think it‟s very exciting. I think it‟s worthwhile to sort of embark on that 
endeavor.” (Respondent 781) 
 
“I‟m all for it. I think it‟s a great idea. I don‟t really know much about the issue 
or the details of what it all entails as far as how do you take individuals that are 
suited for it, but I think it‟s a great idea.” (Respondent 692) 
 
“Oh, my take is that I think they [pharmacogenetic tests] have a tremendous 
potential benefit. Obviously I‟m a radiation oncologist, but over 50% of our 
patients are joint patients who also get chemotherapy, and in fact the response or 
the mechanism by which they metabolize the by-product of their chemotherapy 
can tremendously impact my radiation treatments. So I‟m very excited to see 
progress and more testing.”  
(Respondent 700) 
These quotes highlight the support pharmacogenetics has in the medical 
community. 
 
11. Pharmacogenomics – patient views: Comments related to perceived opinions 
about how patients and members of the public likely view or think about 
pharmacogenomics. Healthcare providers commented about how patients will 
have issues of confidentiality, privacy, and finances. In their understanding, these 
issues come from how patients view their genetic information as reflection of 
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oneself and that it is personal. Furthermore, healthcare providers explained how 
finances could play a role in decision-making: 
“Well I think that the...even though in the old days one of the decision points 
wasn‟t cost, now that will be. And the reason is as much as we hate to admit it, 
one of the stressors and one of the points for patients to make decisions is 
financial burden.” 
 (Respondent 700) 
Respondents also shared the opinion that some patients are just going to refuse the 
use of pharmacogenetic testing for their own personal reasons. Examples of these 
are as follows: 
“ ...I have some [patients] who are going to fight any test you give them. There 
are some that don‟t care.” (Respondent 347) 
 
“..There‟s some skepticism with testing here. You know, all the time I do 
pulmonary function testing on people and it‟s pretty concrete and easy to 
interpret, and people all the time fight that. They‟ll smoke and say „oh, I don‟t 
have any emphysema changes,‟ or anything like that. So I think some people 
would, as far as patients they‟d say that‟s great information for me, but there 
would be some who would put up walls.” (Respondent 347) 
A cultural factor was mentioned by one provider: 
“A lot of it has to do with culture. They don‟t...they won‟t do something unless 
they absolutely feel that it‟s necessary. Like it‟s an emergency then they need to 
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get this done or something bad‟s gonna happen. Especially with our population 
[CSKT].”  
(Respondent 692) 
 
12. Pharmacogenomics risks: Comments about the risks of pharmacogenomics tests 
to the patient or the provider. Concerns have surfaced regarding employers or 
insurance companies accessing genetic data. Healthcare providers mentioned how 
the risk of incidental findings may stem from initial benefits of an individual 
using a pharmacogenetic test.  
“Insurance companies getting ahold of the information is the big thing. I have my 
own personal beliefs on insurance but that‟s not what this interview is about. But 
I do believe that they [insurance companies], in the...the way that they manage 
health care for the people that they are supposed to be taking care of, they‟ve 
actually caused harm and have done better at managing their stock holders‟ 
interests rather than the patients‟, and they‟ll use information against the patient 
rather than for the patient‟s benefit.” (Respondent 100) 
Another major risk that was mentioned by several respondents was the issue of 
pharmacogenetic tests being substituted for clinical judgement. This risk stems 
from pharmacogenetics not resulting in their proposed benefits. 
“We get excited in the medical field about something that seems like it‟s going to 
be, you know, life-changing, in terms of how we do things, and it turns out not so 
much, or what we thought was going to happen turns out it was the opposite, or, 
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you know, we‟ve all lived through those kinds of big changes. So there‟s always 
that potential risk.” (Respondent 781) 
In contrast, some healthcare providers did not have any immediate knowledge of 
risks associated with pharmacogenetic testing. 
 
13. Pharmacogenomics test – important attributes: Comments about important test-
related attributes that the informant would consider in ordering decisions. This 
theme also includes comments related to ordering process preferences as well as 
patient-attributes that would affect pharmacogenomics test ordering decision. The 
idea of a pharmacogenetic test in form of a panel that could analyze multiple 
genes was asked. Healthcare providers were ok with this concept as long as panel 
proved useful, was accompanied with interpretation materials, was affordable, and 
had a quick turn-around time. 
“You‟d want to get them [patients] treated. You wouldn‟t want to wait for a turn 
around for results. We want to start treatment right away...” (Respondent 692) 
Healthcare providers also stated that one important attribute of implementing a 
pharmacogenetic test would be for it to be similar to other blood tests already 
established in the clinic. One respondent mentioned that ordering of a 
pharmacogenetic test should be: 
“As easy as possible. Honestly it‟d be nice if...we do blood draws all day, every 
day. It would be nice if all the labs, like we go through Kalispell Regional, if they 
were set up through this program. It does...I don‟t want, it would make I think a 
lot of nurses and doctors not use it as much if they had to package it up separately 
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and send it out differently, you know it‟s something that took a lot of extra time.” 
(Respondent 543) 
 
14. Pharmacogenomic test – result preferences: Comments related to providers 
preferences for pharmacogenomic test results. There were variable responses by 
healthcare providers in their preference in what pharmacogenetic research results 
should contain. It ranged from respondents who didn’t have much background in 
genetics or pharmacogenetics that opted for just the interpretation of results, while 
more informed respondents requested an all-inclusive report of results. One 
healthcare provider went in detail to what information they would like included in 
the results. 
“...Anything that bears on the metabolism of the drug, not only the rate but the 
differences like the metabolites, other substrates or inhibitors. But then you want 
to know what‟s the – how do I put this – it‟s not something we can know yet I 
think. Which receptors are really significant in the treatment of this and what‟s 
their sensitivity and level of disregulation?” (Respondent 179) 
Another specified result preference was to provide the relevance of genetic 
information findings was to commonly used drugs in healthcare. 
 
15. Provider context: This theme was created to identify the location (i.e. Missoula, 
MT; Polson, MT) and tribal affiliation status of the informant.  
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16. Ranking justification: This theme includes all comments related to the card 
exercise where informants justified category rankings of three examples of 
pharmacogenetic tests in order of least important to most important. This theme 
also includes comments that provide insight into whether decisions were based on 
the informant’s clinical experience or on principles of medical ethics. Comments 
also include preliminary justifications in the event that the informant changed 
ordering during the exercise. Many healthcare providers initially commented on 
the equal value of each of the three pharmacogenetic tests for different reasons 
before ranking them. Healthcare providers ranked according to main need for test 
in their practice, validation of tests, and clinical utility. All but one of the 
healthcare providers ranked the pharmacogenetic test for drug efficacy in their top 
two choices due to the potential of it being able to eliminate the process of trial 
and error of effectively prescribing anti-depressants. 
At times, pharmacogenetic tests for drug efficacy and adverse events were 
grouped together as most valuable in healthcare. One respondent explained: 
“I would put efficacy and adverse events as being equivalent kinds of information. 
You know, any medical treatment is based on a ratio – weighing a benefit to risk. 
Anything that can make that ratio better is helpful to us clinically. And so being 
able to choose based on efficacy or likelihood of adverse events maximizes that 
ratio for us.” (Respondent 933) 
 When providers were asked to choose only two pharmacogenetics tests that they 
would want implemented in their clinics, the test for dosage and monitoring was 
commonly dropped. Most healthcare providers felt that there was already an 
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effective approach to dosing and monitoring that, if need be, could be 
accomplished on their own without a test. One provider was asked which 
pharmacogenetic test they would drop, their response was: 
“Dosage, if we know we need a bigger dose we‟ll get there eventually with or 
without a genetic test.” (Respondent 743) 
Another respondent explained their reason for choosing to drop pharmacogenetic 
test for dosage and monitoring: 
“The warfarin example is one that I think is, we probably don‟t even need the 
drug testing. I‟ll know in five days what the right dose would be. And by then we 
probably don‟t even have the test result back, and we‟ve gotta start, we‟ve gotta 
start that day we know they‟ve got a clot.” (Respondent 376) 
There are various rankings of these pharmacogenetic tests and the reasons are 
variable amongst physicians. This suggests that implementation of 
pharmacogenetics will be site and discipline specific. 
 
17. Rural community specifics: Comments identifying factors that are unique to, or 
particularly present or absent in rural communities. Main comments related to this 
theme explained how Montana is ―sheltered‖ from a lot of new advances in 
medicine. Futhermore, healthcare providers explained that people from rural areas 
are more resistant to new therapies relative to their experiences outside of 
Montana. One provider spoke on several issues for pharmacogenetic testing in 
rural areas: 
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“I would think small towns would be a little bit more user friendly for the patient 
and the pharmacist. But so much of it is driven by third-party payers, whether 
they have to get mail order or not, drives where they‟re gonna get their drugs. So 
it actually, I think, depends more on the third-party payer.” (Respondent 961) 
Some provoked questions as to how insurance companies and cost will affect 
rural communities in getting access to pharmacogenetic testing. Overall, there 
were not many comments related to this theme, but it still provided valuable 
insight into rural considerations for the implementation of pharmacogenetic 
testing. 
 
18. Tribal community specifics: Comments identifying factors that are unique to, or 
particularly present in or absent from tribal communities. Notable issues unique to 
tribal communities were expressed by healthcare providers as historical trauma, 
negative history with research, poverty, lack of education, lack of resources, and 
high incidences patient non-compliance. These were mentioned as issues that 
limit the uptake of pharmacogenetic testing. Another issue revolved around the 
way tribal people view their genetics. One provider described this: 
“And in some regards people [tribal] relate the two [genetics and cultural 
identity], that your genetics is part of your cultural identity, and therefore there is 
always the potential that if we‟re analyzing one, we‟re analyzing the other, and 
therefore they‟re both able to be at risk.” (Respondent 781) 
In contrast, healthcare provided enhancers that exist in tribal communities that are 
unique to them. For example, tribal communities have two resources for 
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healthcare, Indian Health Services and Tribal Health. To this end, providers 
mentioned how it would be of value to get these two healthcare entities on board 
to increase opportunities for testing implementation. One respondent emphasized 
this point: 
“Tribal Health is a huge thing. Indian Health Services is a huuuuge entity. 
Powerful. Across the nation.” (Respondent 663) 
Furthermore, providers commented that it would be an advantage to educate 
“opinion-makers” (i.e. tribal elders, tribal council, and THHS department heads). 
However, in educating tribal patients it has proven difficult to educate them in 
groups. This suggests that there may be a need to develop different modes of 
educating this patient population. 
 
19. Trust: Comments related to patient or community trust toward providers, genetics, 
or other entities and concepts such as the US government. May include both 
current level of trust as well as comments related to building and losing trust. In 
terms of community trust, the majority of healthcare providers discussed the 
incidence of past negative research conducted with AI/AN populations and how 
this role plays into the issues of trust: 
“That willingness to trust may be more of an issue than in some communities 
[non-native] who haven‟t experienced that [research abuse]. Even though this 
particular community [CSKT] hasn‟t, I don‟t think, experienced any 
direct...trauma, in the sense of genetics and testing and experimentation and 
research...But because native people in general have, we all sort of identify with 
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that and we don‟t want that to happen to us [native people]. I think that‟s a real 
and reasonable fear and anxiety that people [native] have.” (Respondent 781) 
 
“...there‟s quite a lot of historical trauma with Native Americans trusting 
primarily governments and authority figures because of the way history has 
played out for us Native Peoples.” (Respondent 775) 
These data emphasized the importance of reassurance by researchers that they 
will honor their intentions of only looking at genetics related to drug response and 
avoid the opportunity of looking more broadly. 
 
3.4.  DISCUSSION 
The purpose of this study is to evaluate the potential value of pharmacogenetics 
research in healthcare to address health inequalities amongst the CSKT community. This 
study used interviews to explore healthcare providers’ knowledge and opinions of 
pharmacogenetics research, and its translation into rural Montana healthcare systems. 
Healthcare providers discussed their understanding of general genetic concepts and how 
they relate to the field of pharmacogenetics research and its associated future clinical 
utility. The majority of participants involved concluded that pharmacogenetics research 
would be beneficial in its translation into the clinic. Amongst participants, concerns of 
cost issues, ethical considerations, privacy issues, mistrust, and reluctance due to 
misconceptions and lack of education were the main barriers to the implementation of 
pharmacogenetic testing. Evidence shows that these concerns are common amongst the 
medical community and have been acknowledged in previous studies investigating the 
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opinions and views about pharmacogenetics of healthcare providers from  U.K. and U.S. 
populations (Fargher et al., 2007; Roth et al., 2011) 
The views from the healthcare professionals living in rural northwestern Montana 
were evaluated to assess knowledge gaps, barriers and enhancers, and cultural factors 
specific to this region of Montana in the uptake of pharmacogenetics. Healthcare 
professionals interviewed in this study represented a diverse background and range of 
disciplines. This provided sources of information from providers of tribal affiliation, 
providers with experience in serving rural and tribal populations, and providers familiar 
with socioeconomic barriers and enhancers in rural and tribal areas. Furthermore, views 
from various healthcare professionals provided information on clinical utility and 
educational needs across disciplines. One main concern of healthcare professionals was 
that cost issues may arise if pharmacogenetic testing was not adopted by healthcare 
entities, such as Tribal Health, which are the main sources of healthcare in AI/AN 
communities and provide them with free services. One healthcare provider explained how 
free healthcare for the CSKT community was a unique characteristic of tribal populations 
because the U.S. government made an agreement with AI/AN communities that they 
would provide them with health amenities. Other cultural barriers mentioned by 
healthcare professionals were issues of mistrust due to historical events related to 
genetics research in AI/AN populations that resulted in misuse of tissue specimens and 
power. This issue of mistrust comes up often  in literature associated with AI/AN 
participation in research and reiterates the importance of working with tribal groups. For 
example, misuse of tissue specimens took place when the Havasupai tribe of Arizona 
agreed to participate in a genetics study with Arizona State University to investigate the 
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high incidences of type II diabetes in the Havasupai community (Harmon, 2010). 
Through understanding the negative history behind genetics research with AI/AN 
populations we are better equipped in addressing these cultural barriers. Another cultural 
barrier highlighted in interview data was lack of genetics education that may result in 
opposition to pharmacogenetic testing and therefore prevent CSKT community members 
from receiving the benefits of this service. However, there exist enhancers that can help 
overcome these barriers such as educating tribal leaders (i.e. Tribal Health department 
heads, Tribal Council, and Cultural Committee Members) about pharmacogenetics and 
the potential clinical utility of pharmacogenetic testing. This would be wise in that these 
tribal leaders are the initial decision-makers of the CSKT community and their support in 
this research increases the acceptance of  pharmacogenetic test implementation.  
This study used exploratory qualitative methods to address healthcare provider 
views in pharmacogenetic research, and furthermore to assess the feasibility of 
implementing pharmacogenetic tests into Tribal Health clinics. Knowledge gained from 
interviews will assist in whether pharmacogenetic testing will be accepted and if so, 
develop strategies to create an implementation model that fits with rural and tribal 
healthcare facilities. Gathering views and attitudes from healthcare professionals is 
necessary to determine how best to deliver pharmacogenetic testing services and the 
impact of these testing services in rural and tribal communities. 
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CHAPTER 4 
 
PATIENTS’ VIEWS ON PHARMACOGENETICS AMONGST THE 
CONFEDERATED SALISH AND KOTENAI TRIBES 
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4.1.  INTRODUCTION 
Since the completion of the Human Genome Project, there have been increased 
efforts to learn more about genetic variation in relation to health issues. Significant 
advances in knowledge about pathways affected by genetic variation have provided new 
ways in understanding humans. Pharmacogenetics is the field of study that focuses on 
variation in drug response due to genetic factors in different populations (Roses, 2001; 
Vesell, 2000; Ventola, 2011). The benefits of pharmacogenetics include the potential to 
identify sources of the aforementioned interindividual variability in drug disposition and 
response in efforts to create safe and effective ways to prescribe medications through the 
use of pharmacogenetic tests (Eichelbaum et al., 2006; Kitzmiller et al., 2011; Crews et 
al., 2012; Johnson et al., 2012). Furthermore, an added goal of pharmacogenetics research 
is to evaluate genetic variation in all world populations to better understand 
interindividual variability in drug response (Ventola, 2011).  
However, American Indian and Alaska Native (AI/AN) populations in the U.S. 
have traditionally not been included in pharmacogenetics research; and therefore, may be 
overlooked in the advancement of personalized medicine. Although pharmacogenetics 
offers opportunity to improve patient and population health outcomes, indigenous 
communities may differ in their judgement about its priority compared to other health 
research and world populations. Currently, only a few studies exist that explore the lay 
persons views about pharmacogenetics research from U.S. and U.K. European, African 
American, and Asian populations (Almarsdóttir et al., 2005; Bevan et al., 2003; Condit 
and Bates, 2005).  In order to successfully conduct pharmacogenetics research and 
facilitate its translation into Tribal Health clinics, it is of value that discussions exist 
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amongst the CSKT community. There is no clear model of how this is to be achieved; 
however, the right place to start is with our partner communities to develop a model that 
best fits their community needs and priorities. Therefore, to assess the perceptions and 
opinions of AI/AN participation in pharmacogenetics research and its translation into the 
clinic, we have worked with the CSKT to identify barriers and gain information about the 
acceptability of pharmacogenetics research and pharmacogenetic testing, and discuss 
strategies to disseminate research results.  
In this study, we have used the qualitative methods of focus groups CSKT 
volunteers who receive their healthcare at Tribal Health facilities. Focus groups are an 
effective method that allows open discussions with participants to as well as opportunities 
for the researchers’ to ask for elaboration on participant responses in relation to other 
participants (Morgan, 1996; Powell and Single, 1996; Farnsworth and Boon, 2010; 
Duggleby, 2005). For these reasons, we chose to use focus groups as a way to assess 
attitudes of the CSKT community towards pharmacogenetics research, pharmacogenetics 
testing, and input regarding dissemination of research findings. This method allows 
researchers to encourage people who may feel intimidated by, or unwilling to, participate 
in individual interviews, who have trouble reading and writing, or who feel they ―have 
nothing to say.‖ On-going consultation with tribal authorities and the CPAC during the 
research process ensured that the focus group guide was informed by local knowledge 
and expertise, and implemented appropriately as discussed in Chapter 2. The focus of this 
study was to generate discussions that address the ethical concerns of pharmacogenetics 
research, how to develop pharmacogenetic studies in the CSKT community, and how, 
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and when, should pharmacogenetic study results be returned back to the CSKT 
community.  
 
4.2.  METHODS 
 
4.2.1  STUDY SUBJECTS 
Approval for this research was obtained from the CSKT Tribal Council, the 
CSKT Tribal Health and Human Services Department, and the Institutional Review 
Boards (IRBs) of the University of Montana and the University of Washington. Prior to 
initiating any research procedures, written consent was obtained using forms approved by 
the IRBs. To date, CSKT subjects 18 years and older (n=7) were recruited for 
participation in focus groups by CPAC members and University of Montana researchers. 
Focus groups were stratified by age: <40 years of age (n=4) and ≥40 years of age (n=3). 
All participants were female. 
 
4.2.2  FOCUS GROUPS 
Focus groups were audio recorded and observational field notes were taken for 
thorough interpretation of views on pharmacogenetics research. The moderator’s guide 
described in Chapter 2 that was developed jointly by researchers and community 
members was used. The focus group is a work-in-progress as we have held only 2 focus 
groups thus far. In one case, a participant arrived later and therefore we performed an 
interview. This interview data will be included with the data from the focus groups. The 
focus groups last approximately two hours. In conducting the focus groups, the moderator 
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welcomes the participants and discusses ground rules concerning confidentiality and 
informed consent. All focus groups were assigned a color in place of their name to de-
identify participants during the audio recording. During the focus group, members of the 
group were asked a series of open-ended questions revolving around three main topics: 1) 
the field of pharmacogenetics 2) clinical utility of pharmacogenetic tests 3) dissemination 
of results back to community. When appropriate, facilitators used storytelling as a means 
of communicating focus group topics to the group members. An important focus of the 
discussion was to determine whether pharmacogenetics research provides benefits 
applicable to the needs of the CSKT community. Furthermore, focus group participants 
were asked to identify potentially culturally-relevant strategies to implement 
pharmacogenetic testing. Finally, focus group participants were asked questions that 
addressed the issue of disseminating results and how best to share research results in an 
understandable format.  
 
4.2.3  QUALITATIVE ANALYSIS 
Initial analysis of focus groups included content analysis of handwritten notes 
taken at time of focus group discussions. Themes that emerged from these notes are 
described in the results section. Further analysis worked to group responses based on 
meanings, themes, and patterns that are included in the moderator’s guide during the 
analysis process. Research experts and trained graduate students worked together to 
develop a coding thematic scheme to assess views of the CSKT patient community using 
the Dedoose © qualitative analytical software package (Los Angeles, CA). The full study 
team will review and discuss all summary results with our CSKT community partners  
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4.3  RESULTS 
 
4.3.1  FOCUS GROUP SUMMARY 
Results of the focus groups are preliminary as we have only completed 2 focus 
groups (7 subjects total). Our intent is to recruit approximately 30 CSKT members. The 
first two focus groups had smaller than anticipated participation (3-4 people vs. the 
intended 6-8 people); therefore, more focus groups may have to be conducted with fewer 
people. As described earlier, the format of the moderator’s guide was divided into three 
main categories and results will be summarized relative to these categories: 1) the field of 
pharmacogenetics , 2) clinical utility of pharmacogenetic tests, and 3) dissemination of 
results. 
 
4.3.2  FIELD OF PHARMACOGENETICS RESAERCH 
Participants’ views in this topic were related to knowledge of pharmacogenetics 
research, attitudes towards pharmacogenetics research (enhancers and barriers), and 
cultural factors. 
 Knowledge of pharmacogenetics research: Comments related to how 
knowledgeable the participants currently feel about pharmacogenetics. When 
participants were asked whether they had heard that genetics played a role in drug 
response, more than half responded ―yes‖ and needed no further clarification. In 
particular, a few participants began talking about their experiences with 
pharmacogenetics such as sensitivities to pain medications.  
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 Attitudes towards pharmacogenetics research: Participants discussed views about 
this type of research in non-CSKT populations as well as CSKT populations. 
Participants were asked questions regarding views on pharmacogenetics research, 
participation in this type of research, and materials used for pharmacogenetic 
research studies. Positive attitudes were a consensus in conducting research in 
both populations and participants described how pharmacogenetics is beneficial 
and needed in order to move research forward. Some participants commented on 
their willingness to be a part of this type of research for the betterment of future 
generations of the CSKT community. Some enhancers described by participants 
were to provide education about the research project to increase uptake of 
pharmacogenetics research. This education should involve all levels of the 
community (i.e. tribal council members, tribal health affiliates, lay CSKT 
community). Another enhancer of pharmacogenetics research included working 
with trusted Tribal Health and Human Services physicians, CSKT Tribal Council, 
and both the Salish and Kootenai Cultural Committees to help earn the trust of the 
CSKT community. One participant made it clear that throughout the research 
project the researchers should keep them [CSKT community] involved and ―be 
transparent all the way through.‖ Barriers that could obstruct or limit the 
participation of CSKT members in pharmacogenetics research included lack of 
education. 
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 Cultural factors: Participants were asked questions about cultural concepts to 
keep in mind when conducting pharmacogenetics research. Participants’ 
comments included consciousness that there are three different tribes on the 
Flathead Indian Reservation, and that there exist different beliefs and cultural 
practices amongst them. Furthermore, researchers should be aware of CSKT 
people who still believe in their traditional medicines and do not practice western 
medicine. Cultural enhancers include working at the pace of the CSKT 
community and respecting their individual cultures. Participants also described 
how there were many barriers with the elders in the CSKT community who don’t 
believe that any type of research is necessary. We also queried participants about 
the types of information researchers may gather, such as medical records, 
completed surveys, questionnaires, or interviews, and samples of blood or other 
parts of the body. When asked questions concerning these forms of information, 
participants felt that it would be fine for researchers to have access to their 
medical records, but would like an explanation and to give permission before 
hand. Others felt that the use of their medical records was a sensitive issue and 
had concerns about how information would be used or the extent of access to this 
information. A majority of participants felt that the use of surveys, questionnaires, 
and interviews as a tool for gaining information would be more appropriate 
because they preferred face-to-face contact with researchers. In terms of 
requesting blood samples or other tissue samples, attitudes were split. Some felt 
that it would be alright to give blood and a couple of participants had mentioned 
that a request for medical records was more sensitive than giving a blood sample. 
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Others were more hesitant to give a blood sample because they felt it was very 
personal and were unsure of its implications. 
 
4.3.3  CLINICAL UTILITY OF PHARMACOGENETIC TESTS 
Participants’ views on this topic were explored related to attitudes towards 
available genetic tests, barriers for implementing genetic tests into the clinic, and ways to 
remove these barriers. 
 Attitudes towards genetic tests for warfarin and tamoxifen: Participants discussed 
positive factors about the adoption or use of available specific pharmacogenetic 
tests for warfarin and tamoxifen. One participant reported that it would be ―we’d 
be going backwards‖ if we did not to take advantage of available 
pharmacogenetic tests. One benefit of pharmacogenetic testing was the possibility 
that Tribal Health would be saving money by limiting the prescription of drugs 
that aren’t helping. Specifically, one participant mentioned how the benefit in 
taking a tamoxifen test would save time and money, insisting that time would be 
saved in prescribing and money would be saved in a therapy that doesn’t work. 
Participants were also asked to choose which pharmacogenetic test they preferred 
if they could only afford one in Tribal Health. Some chose the tamoxifen test over 
a warfarin test and justified this choice partly due to the ―seriousness and 
scariness of the disease [breast cancer]‖ associated with the tamoxifen test. Others 
had mentioned choosing the test by determining which would have the higher 
need amongst the community in terms of patient numbers as well as which would 
be most cost-effective. 
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4.3.4  DISSEMINATION OF RESULTS 
Participants’ views in this topic were related to attitudes towards kinds of research 
information to share and best ways to share research findings. 
 What kind of research information to share: Participants wanted research 
information pertaining to kinds of medications being focused on, impact of the 
research, and results elicited from the research to be shared publicly with the 
CSKT community. One participant mentioned that the return of results should 
highlight the benefits to the community and future generations. 
 
 Best ways to share information: Participants expressed views about the best ways 
to share research project information and results. Participants identified several 
strategies in sharing information with the CSKT community. Some of these 
strategies include: go through Char-Koosta News to report research information, 
community meetings, utilize TV and radio news, presentations at Salish Kootenai 
College (CSKT tribal community college), and use of pamphlets and written 
materials.  
 
4.4  DISCUSSION 
Focus group data from CSKT members are still in the initial stages. Nevertheless, 
emerging themes reveal significant insights pertaining to the views and attitudes of CSKT 
members about pharmacogenetics research, pharmacogenetic testing, and sharing of 
research results. CSKT views were overall positive in acknowledging the potential 
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benefits of pharmacogenetics; however, explanations of implications of 
pharmacogenetics were needed. Potential harms of pharmacogenetics were a huge 
concern of participants and some of these concerns were rooted in misconceptions 
genetics research. This suggests a lack of knowledge in the area of genetics research, 
which can be improved through educational efforts. Furthermore, CSKT participants 
expressed enthusiasm for the use of pharmacogenetic tests in providing therapeutic 
efficacy for severe disease cases. This provides insight to priority needs within the CSKT 
community and perhaps implementing a pharmacogenetic test around this priority may 
increase uptake of pharmacogenetics into Tribal Health clinics. In contrast, some CSKT 
members mentioned that cultural barriers exist amongst the broader CSKT community 
that may limit the use of pharmacogenetic tests by tribal patients. One concern was that 
elders have a strong belief in traditional medicines over westernized medicine and 
therefore may be opposed to using available testing services. However, one participant 
mentioned that through consistent discussions with the older populations, this may 
facilitate a more positive outlook on pharmacogenetics research. 
 In regards to developing strategies to facilitate the return of research results, 
CSKT members provided various avenues of disseminating results to the broader CSKT 
community. In previous studies working with AI/AN populations, researchers failed to 
share research findings with the community understudy. Thus, discussions about 
dissemination strategies are a key component in changing the shape of traditional 
research and provide a foundation for trust to be established amongst researchers and 
AI/AN communities. 
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In summary, this research will provide insight into the obstacles that exist in 
implementation of pharmacogenetic research and pharmacogenetic testing (i.e. Tribal 
Health’s available resources, guidance for providers in the use of pharmacogenetics tests, 
and cultural sensitivities), and how these barriers may be overcome to deliver 
pharmacogenetic testing more broadly to the CSKT community. Furthermore, focus 
groups data will provide guidance on how best to develop culturally relevant and 
appropriate tools for dissemination of pharmacogenetic research results back to the 
CSKT community. The next steps for this project are to complete focus groups and 
analyze focus group data. Through this research we hope to change how drugs are 
administered in AI/AN communities through implementation of pharmacogenetic testing. 
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CHAPTER 5 
 
CONCLUSION 
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The focus and intent of my thesis research was to work in partnership with the 
CSKT community to evaluate the value of pharmacogenetics and identify limiting factors 
that may interrupt its implementation into local healthcare facilities. To address this goal, 
I utilized a variety of CBPR methodologies to (1) engage and educate CSKT community 
members about the potential benefits of pharmacogenetics research and its applications, 
(2) evaluate healthcare professional, and (3) CSKT community views of 
pharmacogenetics research and its translation into the clinic. These CBPR methods are 
essential in understanding barriers and enhancers for implementing pharmacogenetics 
into the CSKT community. Results obtained from this thesis will continue to inform and 
guide this research project in a culturally appropriate manner so that research goals are 
relevant to the health issues of the CSKT community. In addition, views of healthcare 
providers and the CSKT community will prove valuable in future implementation of 
pharmacogenetic testing and dissemination of research project findings. 
Progress in the field of pharmacogenetics has provided evidence for its potential 
benefits in personalizing medicine. Knowledge of major genetic variants in CYP450 drug 
metabolizing enzymes and other  enzymes (i.e.thiopurine methyltransferases (TPMT), 
UDP glucuronosytransferases (UGTs)) has resulted in recognition of their clinical 
relevance in patient drug response (Crews et al., 2012; Eichelbaum et al., 2006; Evans 
and Relling, 1999). Genetic variability has the potential to result in adverse drug 
reactions. In 2006, the FDA recorded adverse drug reactions as the fourth leading cause 
of death in the United States. Pharmacogenetics provides the opportunity to identify 
patients at high risk of adverse drug reactions, as well as improving drug efficacy, 
through understanding and discovering mechanisms underlying interindividual 
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variability. The gene-drug pairs that have been characterized to date are already being 
adopted by FDA and incorporated into drug labeling along with the CPIC developing 
prescribing guidelines. For example, TPMT testing is recommended before starting 
treatment with azathioprine (Imuran) because of known blood toxicities of patients with 
TPMT deficiency (Eichelbaum et al., 2006). Another example is HLA-B (major 
histocompatibility complex, class I, B) testing that is recommended before starting 
carbamazepine or abacavir treatment due to known HLA-B variants that can induce 
Stevens-Johnson syndrome and other severe hypersensitivity reactions (Kitzmiller et al., 
2011). These aforementioned examples show evidence of interethnic variability in 
pharmacogenetic variability. Combined efforts in discovering sources of interindividual 
variability and how this varies further across ethnic groups is now a research topic of 
interest. So far, population studies in pharmacogenetics have largely included European, 
Asian, and African populations, with few studies targeting indigenous groups (Fohner et 
al., 2013; Jaja et al., 2008; Limdi et al., 2008). To ensure that pharmacogenetics reaches 
its optimal clinical utility, pharmacogenetics research should include all members of 
society and the extent of pharmacogenetic variability across ethnic populations should be 
studied. Therefore, the broad goal of this thesis was to include AI/AN populations in 
pharmacogenetics research and to determine and evaluate the value of pharmacogenetics 
in this population.  
Issues of mistrust exist when conducting research with AI/AN populations due to 
past abuses of genetics research that were described in the Introduction. Fortunately, in 
recent years there has been a demand by both community and public health researchers 
for new research models that encompass both community and researcher expertise. One 
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research model that has emerged from these demands is CBPR, which promotes 
community involvement at every stage of research and provides a framework to conduct 
collaborative research. The growing support and success of CBPR in health research 
stems from the acknowledgement of the negative history of research conducted with 
AI/AN communities and recognition of the value of community involvement (Thomas et 
al., 2009; Boyer et al., 2011). The goal of implementing a CBPR approach is to work 
productively with our CSKT partners to develop meaningful health outcomes that take 
advantage of community strengths in efforts to increase intervention sustainability.  
The first step was identification and recruitment of key informants of the CSKT 
community to comprise the CPAC. The CPAC represents a diverse sample of the CSKT 
population and helps to provide tribal input to the research process, develop research 
materials, and recruit for focus groups. Monthly meetings are held with the CPAC and 
university researchers to discuss research updates and educate the CPAC about 
pharmacogenetics to create a space for research dialogue. Along with the CPAC 
members, efforts have been made to engage and educate the broader CSKT population 
through workshops, presentations, and the Char-Koosta newspaper. The impact of these 
aforementioned educational tools was evaluated through surveys and on-going 
consultations with the CPAC. The information gained from these surveys suggested that 
community members and CPAC members were retaining basic genetic concepts and 
using pharmacogenetics terminology properly. In addition, community feedback from 
surveys has also included comments related to areas of needed improvement that will 
help guide further educational ventures. 
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There exists limited published literature on investigating healthcare 
professionals’(Fargher et al., 2007; Dodson, 2011; Insitute of Medicine, 2002) and 
patients’ views (Lanie et al., 2004; Condit and Bates, 2005; Almarsdóttir et al., 2005; 
Emery et al., 1998) about pharmacogenetics research and its applicability in the clinic . In 
addition, there is no clear model on how to deliver testing services into healthcare 
facilities. In order for successful implementation of pharmacogenetic tests, there needs to 
be discussions with healthcare professionals, patient community, and policy makers to 
address issues involved in integrating testing services into healthcare facilities. To 
address this lack of dialogue in pharmacogenetics research, we have incorporated 
qualitative methods to explore the views of healthcare providers and CSKT community 
members.  
Healthcare provider interviews were conducted to explore provider views about 
potential benefits and harms associated with pharmacogenetic testing, its acceptability by 
local healthcare facilities, and the evidence and available resources needed to integrate 
pharmacogenetic testing into common healthcare protocols. Many providers agreed that 
pharmacogenetic testing holds potential clinical utility; however, barriers exist that may 
prevent its implementation into the clinic. Some barriers mentioned were issues of cost, 
trust, ethics, and education. Although these barriers exist, healthcare providers mentioned 
enhancers such as educating both healthcare providers and patients about 
pharmacogenetics to relieve any misconceptions. Healthcare providers also described the 
importance of respecting the culture of CSKT community members and recognizing that 
past abuse of research power has resulted in mistrust. Therefore it’s important to explain 
how this research project differs to build trust.  
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Focus groups were conducted with CSKT community members that discussed 
three major concepts: (1) pharmacogenetics research, (2) pharmacogenetic testing, and 
(3) dissemination of research results. The research results of the focus groups are 
preliminary but there is a general enthusiasm for the potential benefits of 
pharmacogenetics research in local healthcare facilities. Comments related to 
pharmacogenetic testing were positive and participants felt that if they are available they 
should be utilized. Results also suggest that there is still a need for education in the area 
of pharmacogenetics and this lack of knowledge may create barriers to the participation 
of CSKT community members in pharmacogenetics research and testing. Furthermore, in 
adhering to the principles of CBPR it is important that research findings be reported back 
to the broader CSKT community. Focus group results highlighted several strategies that 
will be useful in ensuring that research findings are made public to the CSKT in an 
understandable and culturally respectful manner. A few examples of these strategies 
include presentations at SKC, discussion forums, and pamphlets. Results obtained from 
focus groups will be useful in determining unknown barriers and enhancers that exist in 
the CSKT community towards pharmacogenetics research. 
In summary, this thesis has described the CBPR methods developed and utilized 
to work in partnership with the CSKT community in conducting pharmacogenetics 
research. In addition, CBPR has provided a framework to promote community 
involvement that will facilitate unique and relevant outcomes within the CSKT 
community. Because the traditional research approach, in which researchers have already 
developed preconceived research questions and design, has not been successful in 
working with AI/AN populations, this study has shown how CBPR has created 
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opportunities to build capacity amongst research partners, long-lasting relationships, and 
trust. Furthermore, qualitative research findings are the first steps in incorporating views, 
attitudes, and realities of stakeholders in pharmacogenetics research and contributing 
other viewpoints that exist in this field. Future work still needs to be done in completing 
focus groups, data analysis, and using this information to further guide this research. 
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